Publications de recherche

Publications de recherche2023-02-06T14:14:28-05:00

Publications issues de la recherche financée par le GTIC

Tauzin A, Benlarbi M, Medjahed H, Grégoire Y, Perreault J, Gendron-Lepage G, Gokool L, Morrisseau C, Arlotto P, Tremblay C, Kaufmann DE, Martel-Laferrière V, Levade I, Côté M, De Serres G, Bazin R, Finzi A. Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA VaccinationVaccines. 2023; 11(2):242. https://doi.org/10.3390/vaccines11020242.

O’Brien SF, Goldman M, Drews SJ. An expanded role for blood donor emerging pathogens surveillance. CMAJ. January 2023. doi: 10.1503/cmaj.147635-l.

Lin K, Xu K, Daoust R, Taylor J, Rosychuk RJ, Hau JP, Davis P, Clark G, McRae AD, Hohl CM & the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers, the Canadian Critical Care Trials Group. Prognostic association between d-dimer thresholds and 30-day pulmonary embolism diagnosis among emergency department patients with suspected SARS-CoV-2 infection: a Canadian COVID-19 Emergency Department Rapid Response Network study. Canadian Journal of Emergency Medicine. January 2023. DOI: 10.1007/s43678-022-00440-8.

Bergeri I, Whelan M, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X, Valenciano M, Cheng B, Al Ariqi L, Rashidian A, Okeibunor J, Azim T, Wijesinghe P, Le LV, Vaughan A, Pebody R, Vicari A, Yan T, Yanes-Lane M, Cao C, Clifton DA, Cheng MP, Papenburg J, Buckeridge D, Bobrovitz N, Arora RK, Van Kerkhove MD, Unity Studies Collaborator Group. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLOS Medicine. 2022. DOI: 10.1371/journal.pmed.1004107.

Donnici C, Ilincic C, Cao C, Zhang C, Deveaux G, Clifton D, Buckeridge D, Bobrovitz N, Arora RK. Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance. Epidemics. Dec 2022. DOI: 10.1016/j.epidem.2022.100645.

Macdonald LK, Glogauer M, Allison P, Quiñonez C, Madathil S, Rock LD. Canadian dental hygienists’ experiences and perceptions of regulatory guidelines during the COVID-19 pandemic: a qualitative descriptive analysisBMC Health Serv Res. 2022, 1570 2022 Dec 22;22(1570). doi: https://doi.org/10.1186/s12913-022-08925-z.

Brooks SC, Rosychuk RJ, Perry JJ, Morrison LJ, Wiemer H, Fok P, Rowe BH, Daoust R, Vatanpour S, Turner J, Landes M, Ohle R, Hayward J, Scheuermeyer F, Welsford M, Hohl C, the Canadian COVID-19 Rapid Response Network (CCEDRRN) for the Network of Canadian Emergency Researchers (NCER) and the Canadian Critical Care Trials Group (CCCTG). Derivation and validation of a clinical decision rule to risk-stratify COVID-19 patients discharged from the emergency department: The CCEDRRN COVID discharge scoreJACEP Open. 2022; 3:e12868. doi: https://doi.org/10.1002/emp2.12868.

Costiniuk CT, Singer J, Lee T, Langlois MA, Arnold C, Galipeau Y, Needham J, Kulic I, Jenabian MA, Burchell AN, Shamji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Vulesevic B, Lebouché B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. COVID-19 vaccine immunogenicity in people with HIVAIDS. 2023 Jan 1;37(1):F1-F10. doi: 10.1097/QAD.0000000000003429.

Maltseva M, Galipeau Y, Renner TM, Deschatelets L, Durocher Y, Akache B, Langlois MA. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Vaccines. Dec 2022. DOI: 10.3390/vaccines11010030.

Healey GR, Golding L, Schick A, Majdoubi A, Lavoie PM, Vallance BA. Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination. Gut. Dec 2022. DOI: 10.1136/gutjnl-2022-328556.

O’Brien S, Caffrey N, Yi Q-L, Bolotin S, Janjua NZ, Binka M, Quach Thanh C, Stein D, Lang A, Colquhoun A, Pambrun C, Reedman C, Drews SJ. Cross-Canada variability in blood donor SARS-CoV-2 seroprevalence by social determinants of health, Microbiology Spectrum, 10 January 2023, DOI: https://doi.org/10.1128/spectrum.03356-22.

McEvoy CM, Hu Q, Abe KT, Yau K, Oliver MJ, Levin A, Gingras AC, Hladunewich MA, Yuen DA. Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients. Transplant Direct. 2022 Dec 7;9(1):e1401. doi: 10.1097/TXD.0000000000001401. PMID: 36518793; PMCID: PMC9742098.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia M, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART. AIDS:10.1097/QAD.0000000000003469, December 23, 2022. | DOI: 10.1097/QAD.0000000000003469.

Demone J, Maltseva M, Nourimand M, Nasr-Sharif M, Galipeau Y, Alarcon EI, Langlois MA, MacLean AM. Scalable agroinfiltration-based production of SARS-CoV-2 antigens for use in diagnostic assays and subunit vaccinesPLoS One. 2022 Dec 14;17(12):e0277668. doi: 10.1371/journal.pone.0277668. PMID: 36516116; PMCID: PMC9749978. https://pubmed.ncbi.nlm.nih.gov/36516116/.

Park H, Linthwaite B, Dussault C, Halavrezos A, Chalifoux S, Sherman J, Del Balso L, Buxton JA, Cox J, Kronfli N. Factors associated with changes in illicit opioid use during the COVID-19 pandemic among incarcerated people who use drugs in Quebec, CanadaInt J Prison Health. 2022 Dec 19. doi: https://doi.org/10.1108/IJPH-06-2022-0038.

Walmsley S, Ravindran R, Clarke R, Wouters B, Silva A, Gingras A-C, Szadkowski L. COVID-19 breakthrough infections in vaccinated participants of the Safety and Efficacy of Preventative COVID Vaccines sub-studyCan J Infect Dis Med Microbiol. 2022 Dec. doi: https://doi.org/10.3138/jammi-2022-0011.

Fowokan, H. Samji, J. Puyat, N. Janjua, J. Wilton, J. Wong, T. Grennan, C. Chambers, A. Kroch, C. T. Costiniuk, C. L. Cooper, A. N. Burchell, A. Anis. Effectiveness of COVID 19 Vaccines in People Living with HIV in British Columbia and comparisons with a matched HIV-Negative Cohort: A Test Negative DesignInternational Journal of Infectious Diseases. 2022;194(45):E1529-E1536. DOI: 10.1016/j.ijid.2022.11.035.

Round 4: Preliminary Results, ENCORE – Children and COVID-19 Montreal seroprevalence study (May – September 2022).

Naveed Z, Li J, Spencer M, Wilton J, Naus M, García HAV, Otterstatter M, Janjua NZ. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort studyCMAJ. 2022;194(45):E1529-E1536. DOI: https://www.cmaj.ca/content/194/45/E1529.

Naveed Z, Li J, Wilton J, Spencer M, Naus M, Velásquez García HA, Kwong JC, Rose C, Otterstatter M, Janjua NZ; Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus VaccinesJ Am Coll Cardiol. 2022 Nov 15;80(20):1900–8, DOI: https://doi.org/10.1016/j.jacc.2022.08.799.

Paramo M. V., Abu-Raya B., Reicherz F., Xu R. Y., Bone J. N., Srigley J. A., Solimano A., Goldfarb D. M., Skowronski D. M., Lavoie P. M. Comparative analysis of pediatric Respiratory Syncytial Virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada. medRxiv. 2022. DOI: 10.1101/2022.11.18.22282477.

Kronfli N, Dussault C, Maheu-Giroux, M, Halavrezos A, Chalifoux S, Park H, Del Balso L, Cheng MP, Cox J. Importance of occupation for SARS-CoV-2 seroprevalence and COVID-19 vaccination among correctional workers in Quebec, Canada: A cross-sectional studyFront. Public Health, 09 November 2022. DOI: https://doi.org/10.3389/fpubh.2022.1021871.

Results from COVID-19 Vaccination During Pregnancy in Ontario, Report 6, posted at https://www.bornontario.ca/en/whats-happening/resources/Documents/COVID-19-Vaccination-during-pregnancy-in-Ontario_Report6.pdf.

Germain M, Lewin A, Bazin R, Dieudé M, Perreault J, Boivin A, Grégoire Y, Renaud C. Cohort profile: A Quebec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). medRxiv. 2022 Nov 11. doi: https://doi.org/10.1101/2022.11.09.22282156.

Butler-Laporte G, Povysil G, Kosmicki JA, Cirulli ET, Drivas T, Furini S, Saad C, Schmidt A, Olszewski P, Korotko U, Quinodoz M, Çelik E, Kundu K, Walter K, Jung J, Stockwell AD, Sloofman LG, Jordan DM, Thompson RC, Del Valle D, Simons N, Cheng E, Sebra R, Schadt EE, Kim-Schulze S, Gnjatic S, Merad M, Buxbaum JD, Beckmann ND, Charney AW, Przychodzen B, Chang T, Pottinger TD, Shang N, Brand F, Fava F, Mari F, Chwialkowska K, Niemira M, Pula S, Baillie JK, Stuckey A, Salas A, Bello X, Pardo-Seco J, Gómez-Carballa A, Rivero-Calle I, Martinón-Torres F, Ganna A, Karczewski KJ, Veerapen K, Bourgey M, Bourque G, Eveleigh RJ, Forgetta V, Morrison D, Langlais D, Lathrop M, Mooser V, Nakanishi T, Frithiof R, Hultström M, Lipcsey M, Marincevic-Zuniga Y, Nordlund J, Schiabor Barrett KM, Lee W, Bolze A, White S, Riffle S, Tanudjaja F, Sandoval E, Neveux I, Dabe S, Casadei N, Motameny S, Alaamery M, Massadeh S, Aljawini N, Almutairi MS, Arabi YM, Alqahtani SA, Al Harthi FS, Almutairi A, Alqubaishi F, Alotaibi S, Binowayn A, Alsolm EA, El Bardisy H, Fawzy M, Cai F, Soranzo N, Butterworth A; COVID-19 Host Genetics Initiative; DeCOI Host Genetics Group; GEN-COVID Multicenter Study (Italy); Mount Sinai Clinical Intelligence Center; GEN-COVID consortium (Spain); GenOMICC Consortium; Japan COVID-19 Task Force; Regeneron Genetics Center, Geschwind DH, Arteaga S, Stephens A, Butte MJ, Boutros PC, Yamaguchi TN, Tao S, Eng S, Sanders T, Tung PJ, Broudy ME, Pan Y, Gonzalez A, Chavan N, Johnson R, Pasaniuc B, Yaspan B, Smieszek S, Rivolta C, Bibert S, Bochud PY, Dabrowski M, Zawadzki P, Sypniewski M, Kaja E, Chariyavilaskul P, Nilaratanakul V, Hirankarn N, Shotelersuk V, Pongpanich M, Phokaew C, Chetruengchai W, Tokunaga K, Sugiyama M, Kawai Y, Hasegawa T, Naito T, Namkoong H, Edahiro R, Kimura A, Ogawa S, Kanai T, Fukunaga K, Okada Y, Imoto S, Miyano S, Mangul S, Abedalthagafi MS, Zeberg H, Grzymski JJ, Washington NL, Ossowski S, Ludwig KU, Schulte EC, Riess O, Moniuszko M, Kwasniewski M, Mbarek H, Ismail SI, Verma A, Goldstein DB, Kiryluk K, Renieri A, Ferreira MAR, Richards JB. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022 Nov 3;18(11):e1010367. doi: 10.1371/journal.pgen.1010367.

Daroya E, Greya C, Lessard D, Klassen B, Skakoon-Sparling S, Gaspar M, Perez-Brumer A, Adam B, Lachowsky NJ, Moore D, Sang JM, Lambert G, Hart TA, Cox J, Jollimore J, Tan DHS, Grace D. ‘I did not have sex outside of our bubble’: Changes in Sexual Practices and Risk Reduction Strategies among Sexual Minority Men in Canada during the COVID-19 Pandemic. Culture, Health, and Sexuality. 2022 November. DOI: 10.1080/13691058.2022.2139414.

Windsor JW, Caplan L, Ingram RJM, Charlton C, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group. Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel diseaseLancet Gastroenterol Hepatol. 2022 Oct 25:S2468-1253(22)00340-5. DOI: 10.1016/S2468-1253(22)00340-5.

Tauzin A, Gong SY, Chatterjee D, Ding S, Painter MM, Goel RR, Beaudoin-Bussières G, Marchitto L, Boutin M, Laumaea A, Okeny J, Gendron-Lepage G, Bourassa C, Medjahed H, Goyette G, Williams JC, Bo Y, Gokool L, Morrisseau C, Arlotto P, Bazin R, Fafard J, Tremblay C, Kaufmann DE, De Serres G, Richard J, Côté M, Duerr R, Martel-Laferrière V, Greenplate AR, Wherry EJ, Finzi A. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two dosesCell Rep. 2022 Oct 25;41(4):111554. doi: 10.1016/j.celrep.2022.111554.

Zinszer K, Charland K, Pierce L, Saucier A, McKinnon B, Hamelin M-E, Cheriet I, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C. Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, Canada. medRxiv 2022 Oct 10. doi: https://doi.org/10.1101/2022.10.28.22281660.

Ma H., Chan A. K. Baral S. D, Fahim C., Straus S., Sander B., Mishra S. Which curve are we flattening? The disproportionate impact of COVID-19 among economically marginalized communities in Ontario, Canada, was unchanged from wild-type to omicron. medRxiv. 2022. DOI: 10.24.22281104.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia M, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART. medRxiv. 2022. 11.03.22281912; DOI: https://doi.org/10.1101/2022.11.03.22281912.

Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanahary H, Hamelin M-E, McCormack D, Savard P, Longtin Y, Cheng MP, De Serres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H. Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination 1 influences the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. Front Immunol. 2022 Oct 14;13:930252. doi: 10.3389/fimmu.2022.930252.

Bettinger JA, Irvine MA, Shulha HP, Valiquette L, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, McGeer A, Isenor JE, Marty K, Soe P, De Serres G; Canadian Immunization Research Network. Adverse Events Following Immunization with mRNA and Viral Vector Vaccines in Individuals with Previous SARS-CoV-2 Infection from the Canadian National Vaccine Safety NetworkClin Infect Dis. 2022 Oct 31:ciac852. doi: 10.1093/cid/ciac852.

Holder KA, Ings DP, Harnum DOA, Russell RS, Grant MD. Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infectionNPJ Vaccines. 2022 Oct 21;7(1):122. DOI: 10.1038/s41541-022-00546-1.

Sujane Kandasamy, Baanu Manoharan, Zainab Khan, Rosain Stennett, Dipika Desai, Rochelle Nocos, Gita Wahi, Davina Banner, Russell J de Souza, Scott Lear, Sonia S Anand. Perceptions of COVID-19 risk, vaccine access, and confidence: a qualitative analysis of South Asians in Canada. medRxiv 2022.10.21.22281321; doi: https://doi.org/10.1101/2022.10.21.22281321.

O’Brien SF, Caffrey N, Yi Q-L, Pambrun C, Drews SJ. SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron. Viruses. 2022; 14(11):2336. doi: https://doi.org/10.3390/v14112336.

Azeez R, Lotoski L, Dubeau A, Rodriguez N, Reyna ME, Freitas T, Goguen S, Medeleanu M, Winsor GL, Brinkman FSL, Cameron EE, Roos L, Simons E, Moraes TJ, Mandhane PJ, Turvey SE, Bolotin S, Wright K, McNeil D, Patrick DM, Bullard J, Langlois MA, Arnold CR, Galipeau Y, Pelchat M, Doucas N, Subbarao P, Azad MB. Investigating SARS-CoV-2 infection and the health and psychosocial impact of the COVID-19 pandemic in the Canadian CHILD Cohort: study methodology and cohort profile. medRxiv. 2022 Oct 21. doi: https://doi.org/10.1101/2022.10.19.22281242

Chambers C, Samji H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess G, Benoit AC, Buchan SA, Chung H, Kendall CE, Kwong JC, Langlois MA, Lee SM, Mbuagbaw L, Mccullagh J, Moineddin R, Nambiar D, Walmsley S, Anis A, Burchell AN; COVAXHIV Study Team. COVID-19 Vaccine Effectiveness among a Population-based Cohort of People Living with HIVAIDS. 2022 Oct 19. doi: 10.1097/QAD.0000000000003405.

Kimura M, Ferreira VH, Kothari S, Pasic I, Mattsson JI, Kulasingam V, Humar A, Mah A, Delisle JS, Ierullo M, Majchrzak-Kita B, Kumar D, Hosseini-Moghaddam SM. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Transplant Cell Therapy. 2022 Oct;28(10): 706.e1-706.e10. doi: 10.1016/j.jtct.2022.07.024.

Ma X, Li Z, Whelan M, Kim D, Cao C, Yanes-Lane M, Yan T, Jaenisch T, Chu M, Clifton DA, Subissi L, Bobrovitz N, Arora RK. Serology assays used in SARS-CoV-2 seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performancemedRxiv. 2022 Oct 15. doi: doi.org/10.1101/2022.10.13.22280957.

Cable J, Fauci A, Dowling WE, Günther S, Bente DA, Yadav PD, Madoff LC, Wang LF, Arora RK, Van Kerkhove M, Chu MC, Jaenisch T, Epstein JH, Frost SDW, Bausch DG, Hensley LE, Bergeron É, Sitaras I, Gunn MD, Geisbert TW, Muñoz-Fontela C, Krammer F, de Wit E, Nordenfelt P, Saphire EO, Gilbert SC, Corbett KS, Branco LM, Baize S, van Doremalen N, Krieger MA, Clemens SAC, Hesselink R, Hartman D. Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report. Annals of the New York Academy of Sciences. 2022. Doi: 10.1111/nyas.14898.

Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, Wilson K, Wilson SE, Kwong JC. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe OutcomesJAMA Network Open. 2022 Sep 22. doi: https://doi.org/10.1001/jamanetworkopen.2022.32760.

Asamoah-Boaheng M., Goldfarb D. M., Karim M. E., O’Brien S. F., Wall N., Drews S. J., Barakauskas J., Jassem A. N., Grunau B. The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults. The Journal of Infectious Diseases. 2022. Doi: 10.1093/infdis/jiac403.

Chung H, Austin PC, Brown KA, Buchan SA, Fell DB, Fong C, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, Wilson K, Wilson SE, Kwong JC. Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design StudyOpen Forum Infect Dis. 2022 Sep 7;9(9):ofac449. DOI: https://doi.org/10.1093/ofid/ofac449.

Ma H, Yiu KC, Baral SD, Fahim C, Moloney G, Darvin D, Landsman D, Chan AK, Straus S, Mishra S. COVID-19 cases among congregate care facility staff by neighbourhood of residence and social and structural determinants: observational studyJMIR Public Health and Surveillance. 2022 Jul 21. doi: https://doi.org/10.2196/34927.

Mwimanzi FM, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Burns L, Young L, Leung V, Ennis S, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA.  Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccinemedRxiv, 2022.08.08.22278494; doi: https://doi.org/10.1101/2022.08.08.22278494.

Breznik JA, Huynh A, Zhang A, Bilaver L, Bhakta H, Stacey HD, Ang JC, Bramson JL, Nazy I, Miller MS, Denburg J, Costa AP, Bowdish DME, other members of the COVID-in-LTC Investigator Group. Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination. Journal of Immunology, September 28, 2022, ji2200369; DOI: https://doi.org/10.4049/jimmunol.2200369

Butler-Laporte G, Gonzalez-Kozlova E, Su CY, Zhou S, Nakanishi T, Brunet-Ratnasingham E, Morrison D, Laurent L, Afilalo J, Afilalo M, Henry D, Chen Y, Carrasco-Zanini J, Farjoun Y, Pietzner M, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Moussa Y, DeLuca C, Duggan N, Schurr E, Brassard N, Durand M, Del Valle DM, Thompson R, Cedillo MA, Schadt E, Nie K, Simons NW, Mouskas K, Zaki N, Patel M, Xie H, Harris J, Marvin R, Cheng E, Tuballes K, Argueta K, Scott I; Mount Sinai COVID-19 Biobank Team, Greenwood CMT, Paterson C, Hinterberg M, Langenberg C, Forgetta V, Mooser V, Marron T, Beckmann N, Kenigsberg E, Charney AW, Kim-Schulze S, Merad M, Kaufmann DE, Gnjatic S, Richards JB. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022 Sep 28. Doi: https://doi.org/10.1186/s12014-022-09371-z.

Grunau B, Prusinkiewicz M, Asamoah-Boaheng M, Golding L, Lavoie PM, Petric M, Levett PN,   Haig S, Barakauskas V, Karim ME, Jassem AN, Drews SJ,  Sediqi S, Goldfarb DM. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Microbiol Spectr. 2022 Sep 19;0(0):e01315-22 DOIhttps://doi.org/10.1128/spectrum.01315-22.

Pluss O., Campbell H., Pezzi L., Morales I., Roell Y., Quandelacy T. M., Arora R. H., Boucher E., Lamb M. M., Chu M., Bärnighausen T., Jaenisch T. Limitations introduced by a low participation rate of SARS-CoV-2 seroprevalence data. International Journal of Epidemiology (2022). doi: https://doi.org/10.1093/ije/dyac178.

Steinberg N., Allison P. and Levin L. Infection Prevention Strategies Concordance in Canadian Dental Schools During the COVID-19 Pandemic. International Dental Journal (2022). doi: 10.1016/j.identj.2022.07.005.

Lin Y-CJ, Evans DH, Robbins NF, Orjuela G, Hu Q, Samson R,  Abe KT, Rathod B, Colwill K, Gingras AC, Tuite A, Yi QL, O’Brien SF, Drews SJ. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses. Microbiology Spectrum. 0(0):e02811-22. doi: https://doi.org/10.1128/spectrum.02811-22

Akingbola S., Fernandes R., Borden S., Gilbride K., Oswald C., Straus S., Tehrani A., Thomas J., Stuart R. Early identification of a COVID-19 outbreak detected by wastewater surveillance at a large homeless shelter in Toronto, Ontario. Canadian Journal of Public Health. (2022). doi: 10.17269/s41997-022-00696-8.

Fu, Z.; Rais, Y.; Dara, D.; Jackson, D.; Drabovich A.P. Rational Design and Development of SARS-CoV-2 Serological Diagnostics by Immunoprecipitation-Targeted Proteomics. Analytical Chemistry 2022, Epub September 12; doi: https://doi.org/10.1021/acs.analchem.2c01325.

Burrows AG, Linton S, Thiele J, Sheth PM, Evans GA, Archer S, Doliszny KM, Finlayson M, Flynn L, Gong Y, Huang Y, Kasmani A, Moore K, Sanfilippo A, Snelgrove-Clarke E, Tripp DA, Walker DMC, Vanner S, Ellis AK, Asymptomatic Surveillance Testing for COVID-19 in Health Care Professional Students: Lessons learned from a low prevalence settingApril 11, 2022, Research Square, Doi: https://doi.org/10.21203/rs.3.rs-1505764/v1.

Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, Nardone A, Valenciano M, Cheng B, Noel K, Cao C, Yanes-Lane M, Herring BL, Talisuna A, Ngoy N, Balde T, Clifton D, Van Kerkhove MD, Buckeridge D, Bobrovitz N, Okeibunor J, Arora RK, Bergeri I; UNITY Studies Collaborator Group. SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 2022 Aug;7(8):e008793. doi: 10.1136/bmjgh-2022-008793.

Atiquzzaman M, Zheng Y, Er L, Djurdjev O, Singer J, Krajden M, Balamchi S, Thomas D, Oliver MJ, Levin A. COVID-19 vaccine effectiveness in patients with non-dialysis dependent chronic kidney diseases; findings from a population-based observational study from British Columbia, Canada. Kidney international. 2022 Sep 11. Doi:  https://doi.org/10.1016/j.kint.2022.08.027.

Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, Zhang K, Patel Z, Salter B, Yuen ACY, Soon K, -Lau K, Cowbrough B, Radford K, Huang C, Kjarsgaard M, Dvorkin-Gheva A, Smith J, Li QZ, Waserman S, Ryerson CJ, Nair P, Ho T, Balakrishnan N, Nazy I, Bowdish DME, Svenningsen S, Carlsten C, Mukherjee M. Circulating Antinuclear Autoantibodies in COVID-19 Survivors Predict Long-COVID Symptoms. European Respiratory Journal, 2022, 2200970; DOI: 10.1183/13993003.00970-2022.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes D, DeMarco DL, Simons J, Matic N, Montaner JSG, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. Front. Immunol. 2022 September 6. Doi: 10.3389/fimmu.2022.947021.

Nasreen S, Febriani Y, Velásquez García HA, Zhang G, Tadrous M, Buchan SA, Righolt CH, Mahmud SM, Janjua NZ, Krajden M, De Serres G, Kwong JC, Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators. Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design studyClinical Infectious Diseases, 2022; ciac634, https://doi.org/10.1093/cid/ciac634.

Jenkinson JIR, Sniderman R, Gogosis E, Liu M, Nisenbaum R, Pedersen C, Spandier O, Tibebu T, Dyer A, Crichlow F, Richard L, Orkin A, Thulien N, Kiran T, Kayseas J, Hwang SW. Exploring COVID-19 vaccine uptake, confidence and hesitancy among people  experiencing homelessness  in Toronto, Canada: protocol  for the Ku-gaa-gii pimitizi-win qualitative study. BMJ Open. 2022 August 17. Doi: 10.1136/bmjopen-2022-06422.

Bazin R, Rochette S, Perreault J, Fournier M-J, Grégoire Y, Boivin A, Lewin A, Germain M, Renaud C. Development and use of a method based on the anti-N reactivity of longitudinal 1 samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated population. medRxiv 2022.08.15.22278798; doi: https://doi.org/10.1101/2022.08.15.22278798.

Mwimanzi FM, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Burns L, Young L, Leung V, Ennis S, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Brief Report: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine. medRxiv, 2022.08.08.22278494; doi: https://doi.org/10.1101/2022.08.08.22278494.

Fell DB, Dimanlig-Cruz S, Regan AK, Håberg SE, Gravel CA, Oakley L, Alton GD, Török E, Dhinsa T, Shah PS, Wilson K, Sprague AE, El-Chaâr D, Walker MC, Barrett J, Okun N, Buchan SA, Kwong JC, Wilson SE, Dunn SI, MacDonald SE, Dougan SD, Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study. BMJ 2022; 378 :e071416.  Doi: 10.1136/ bmj-2022-071416.

Sadarangani M, Soe P, Shulha HP, Valiquette L, Vanderkooi OG, Kellner JD, Muller MP, Top KA, Isenor JE, McGeer A, Irvine M, De Serres G, Marty K, Bettinger JA; Canadian Immunization Research Network. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort studyLancet Infect Dis. 2022 Aug 11:S1473-3099(22)00426-1. doi: 10.1016/S1473-3099(22)00426-1.

Ferreira VH, Solera JT, Hu Q, Hall VG, Arbol BG, Rod Hardy W, Samson R, Marinelli T, Ierullo M, Virk AK, Kurtesi A, Mavandadnejad F, Majchrzak-Kita B, Kulasingam V, Gingras AC, Kumar D, Humar A. Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings. Nat Commun. 2022 Aug 4;13(1):4489. doi: 10.1038/s41467-022-32235-x.

Richard L, Liu M, Jenkinson J, Nisenbaum R, Brown M, Pedersen C, Hwang S. COVID-19 vaccine coverage and sociodemographic, behavioural and housing factors associated with vaccination among people experiencing homelessness in Toronto, Canada: A cross-sectional study. Vaccines. 3 August 2022. doi: https://doi.org/10.3390/vaccines10081245.

Richard L, Nisenbaum R, Liu M, McGeer A, Mishra S, Gingras A-C, Gommerman JL, Sniderman R, Pedersen C, Spandier O, Jenkinson JIR, Baral S, Mejia-Lancheros C, Agarwal A, Jamal AJ, Ostrowski M, Dhalla I, Stewart S, Gabriel M, Brown M, Hester J, Hwang SW. Ku-gaa-gii pimitizi-win, the COVID-19 cohort study of people experiencing homelessness in Toronto, Canada: a study protocol. BMJ Open. 27 June 2022. doi: https://bmjopen.bmj.com/content/12/8/e063234

Parham KA, Kim GN, Saeedian N, Ninkov M, Richer CG, Li Y, Wu K, Rashu R, Barr SD, Arts EJ, Haeryfar S.MM, Kang CY, Troyer RM. Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants. bioRxiv 2022.07.19.500626; doi: https://doi.org/10.1101/2022.07.19.500626.

Grunau B, Tom J, Asamoah-Boaheng M, O’Brien SF, Drews SJ, Sediqi S, Lavoie PM, Barakauskas V, Goldfarb DM, Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 InfectionsOpen Forum Infectious Diseases, 2022, ofac349, https://doi.org/10.1093/ofid/ofac349.

Choi A, Mâsse L.C., Bardwell S, Zhao Y, Xu YXZ, Markarian A, Coombs D, Watts A, Macdonald A, Dhillon N, Irvine M O’Reilly C, Lavoie PM, Goldfarb D. Symptomatic and asymptomatic transmission of SARS-CoV-2 in K-12 schools, British Columbia, April to June 2021Microbiology Spectrum. 6 July 2022. DOI: https://doi.org/10.1128/spectrum.00622-22.

Watts AW, Mâsse LC, Goldfarb DM, Irvine MA, Hutchison SE, Muttucomaroe L, Poon B, Barakauskas VE, O’Reilly C, Bosman ES, Reicherz F, Coombs D, Pitblado M, O’Brien SF, Lavoie PM. SARS-CoV-2 seroprevalence among public school staff in Metro Vancouver after the first Omicron wave in British Columbia, Canada. medRxiv 2022.07.04.22277230; doi: https://www.medrxiv.org/content/10.1101/2022.07.04.22277230v1.

Breznik JA, Rahim A, Kajaks T, Hagerman M, Bilaver L, Colwill K, Dayam RM, Gingras AC, Verschoor CP, McElhaney JE, Bramson JL, Bowdish DME, Costa AP. Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada. medRxiv 2022.06.28.22277016; doi: https://www.medrxiv.org/content/10.1101/2022.06.28.22277016v1.

Grunau B, O’Brien SF, Kirkham TL, Helmer J, Demers PA, Asamoah-Boaheng M, Drews SJ, Karim ME, Srigley JA, Sediqi S, O’Neill D, Drennan IR, Goldfarb DM. A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 Pandemic. Ann Emerg Med. 2022 Jul;80(1):38-45. doi: 10.1016/j.annemergmed.2022.03.009.

Anand SS, Arnold C, Bangdiwala S, Bolotin S, Bowdish D, Chanchlani R, de Souza R, Desai D, Kandasamy S, Khan F, Khan Z, Langlois M-A, Limbachia J, Lear S, Loeb M, Loh L, Manoharan B, Nakka K, Pelchat M,  Punthakee Z, Schulze K, Williams N, Wahi G. Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study. CMAJ Open 2022 July 5. DOI:10.9778/cmajo.20220031.

Coope RJN, Matic N, Pandoh PK, Corbett RD, Smailus DE, Pleasance S, Lowe CF, Ritchie G, Chorlton SD, Young M, Ally AA, Asano JK, Carlsen RE, Chahal SS, Zhao Y, Holmes DT, Romney MG, Jones SJM, Marra MA. Automated Library Construction and Analysis for High-throughput Nanopore Sequencing of SARS-CoV-2. Journal of Applied Laboratory Medicine, 2022;, jfac054, https://doi.org/10.1093/jalm/jfac054.

Andrew MK, Godin J, LeBlanc J, Boivin G, Valiquette L, McGeer A, McElhaney JE, Hatchette TF, ElSherif M, MacKinnon-Cameron D, Wilson K, Ambrose A, Trottier S, Loeb M, Smith SW, Katz K, McCarthy A, McNeil SA. Older Age and Frailty are Associated with Higher Mortality but Lower ICU Admission with COVID-19. Can Geriatr J [Internet]. 2022 Jun. 1 [cited 2022 Jun. 17]; 25(2):183-96. Doi: https://doi.org/10.5770/cgj.25.546.

Ullah I, Beaudoin-Bussières G, Symmes K, Cloutier M, Ducas E, Tauzin A, Laumaea A, Bégin P, Mothes W, Kumar P, Bazin R, Finzi A, Uchil PD. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. bioRxiv 2022.06.10.495677; doi: https://doi.org/10.1101/2022.06.10.495677.

McEvoy CM, Hu Q, Abe KT, Yau K, Oliver MJ, Levin A, Gingras AC, Hladunewich MA, Yuen DA, Humoral Responses in the Omicron Era following Three-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients, medRxiv 2022.06.24.22276144; doi: https://doi.org/10.1101/2022.06.24.22276144.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis A, Leung V, Holmes DT, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses The Journal of Infectious Diseases, 2022; jiac229, https://doi.org/10.1093/infdis/jiac229.

Oliver MJ, Blake PG. Clinical Utility of COVID-19 Vaccination in Patients Undergoing Hemodialysis. Clin J Am Soc Nephrol. 2022 Jun 1;17(6):779–81. https://doi.org/10.2215/CJN.04930422.

Kanji JN, Nguyen LT, Plitt SS, Charlton CL, Fenton J, Braun S, Marohn C, Lau C, Svenson LW, Hinshaw D, Lutsiak C, Zelyas N, Mengel M, Tipples G. Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021–July 2021). Infectious Diseases. 2022 May 31. DOI: 10.1080/23744235.2022.2080250.

Nasreen S, Calzavara A, Buchan SA, Thampi N, Johnson C, Wilson SE, Kwong JC. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance. Vaccine. 2022 May 26. doi:  10.1016/j.vaccine.2022.04.065.

Breznik JA, Huynh A, Zhang A, Bilaver L, Bhakta H, Stacey HD, Ang JC, Bramson JL, Nazy I, Miller MS, Denburg J, Costa AP, Bowdish DME, other members of the COVID-in-LTC Investigator Group. CMV seropositivity in older adults changes T cell functionality, but does not prevent antibody or cellular SARS-CoV-2 vaccine responses. medRxiv. 2022 May 28. Doi: 10.1101/2022.05.27.22275673.

Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Makovinović A, Coward S, Windsor JW, Caplan L, Ingram RJ. Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG, STOP COVID-19 in IBD Research Group. Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease. Gut. 2022 May 23. Doi: 10.1136/gutjnl-2022-327440.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes D, DeMarco DL, Simons J, Matic N, Montaner JSG, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. medRxiv. 2022 May 21. Doi: 10.1101/2022.05.19.22275026

Brown PE, Fu SH, Bansal A, Newcombe L, Colwill K, Mailhot G, Delgado-Brand M, Gingras AC, Slutsky AS, Pasic M, Companion J, Bogoch II, Morawski E, Lam T, Reid A, Jha P. Ab‑C Study Collaborators. Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults. N Engl J Med. Le 18 mai 2022. doi : 10.1056/NEJMc2202879.

Bhatt M, Zemek RL, Tang K, Malley R, Plint AC, Pham-Huy A, Dawson J, McGahern C, Pelchat M, Arnold C, Galipeau Y, Langlois MA. Antibody Seronegativity in COVID-19 RT-PCR-Positive Children. Pediatr Infect Dis J. Le 9 mai 2022. doi : 10.1097/INF.0000000000003573.

Matic N, Lowe CF, Ritchie G, Young M, Lawson T, Romney MG. Omicron (B. 1.1. 529) SARS-CoV-2 viral load among nasopharyngeal and oral samples compared to other Variants of Concern and impact on diagnostic testing strategy. Clin Microbiol Infect. Le 11 mai 2022. doi : https://doi.org/10.1016/j.cmi.2022.04.022.

Yoo S, Garg E, Elliott LT, Hung RJ, Halevy AR, Brooks JD, Bull SB, Gagnon F, Greenwood CM, Lawless JF, Paterson AD, Sun L, Zawati MH, Lerner-Ellis J, Abraham RJS, Birol I, Bourque G, Garant J-M, Gosselin C, Li J, Whitney J, Thiruvahindrapuram B, Herbrick J-A, Lorenti M, Reuter MS, Liu S, Allen U, Bernier FP, Biggs CM, Cheung AM, Cowan J, Herridge M, Maslove DM, Modi BP, Mooser V, Morris SK, Ostrowski M, Parekh RS, Pfeffer G, Suchowersky O, Taher J, Turvey SE, Upton J, Warren RL, Yeung RSM, Aziz N, Knoppers BM, Lathrop M, Jones SJM, Scherer SW, Strug LJ. HostSeq: A Canadian Whole Genome Sequencing and Clinical Data Resource. medRxiv. Le 10 mai 2022. doi : 10.1101/2022.05.06.22274627.

McClymont E, Albert AY, Alton GD, Boucoiran I, Castillo E, Fell DB, Kuret V, Poliquin V, Reeve T, Scott H, Sprague AE, Carson G, Cassell K, Crane J, Elwood C, Joynt C, Murphy P, Murphy-Kaulbeck L, Saunders S, Shah P, Snelgrove JW, van Schalkwyk J, Yudin MH, Money D; CANCOVID-Preg Team. Association of SARS-CoV-2 Infection During Pregnancy With Maternal and Perinatal Outcomes. JAMA. Le 2 mai 2022. doi: 10.1001/jama.2022.5906.

Reicherz F, Xu RY, Abu-Raya B, Majdoubi A, Michalski C, Golding L, Stojic A, Vineta M, Granoski M, Cieslak Z, Chacko A, Desai N, Sekirov I, Marchant DJ, Lavoie PM. Waning immunity against respiratory syncytial virus during the COVID-19 pandemic. Journal of Infectious Diseases. Le 7 mai 2022. doi: org/10.1093/infdis/jiac192.

Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA (2022). Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. J Infect Dis; jiac199. doi: 10.1093/infdis/jiac199.

Racine É, Boivin G, Longtin Y, Mccormack D, Decaluwe H, Savard P, Cheng MP, Hamelin ME, Carbonneau J, Tadount F, Adams K, Bourdin B, Nantel S, Gilca V, Corbeil J, De Serres G, Quach-Thanh C. The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Influenza Other Respir Viruses; 2022; 1-10. doi: 10.1111/irv.12997

Widdifield J, Kwong JC, Chen S, Eder L, Benchimol EI, Kaplan GG, Hitchon C, Aviña-Zubieta JA, Lacaille D, Chung H, Bernatsky S. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. Lancet Rheumatol. Le 14 avril 2022. doi : 10.1016/S2665-9913(22)00096-0

Watts A.W., Hutchison S.M., Bettinger J.A., Gadermann A., Oberle E., Oberlander T.F., Goldfarb D.M., Lavoie P.M., Masse L.C. COVID-19 Vaccine Intentions and Perceptions Among Public School Staff of the Greater Vancouver Metropolitan Area, British Columbia, Canada. Front. Public Health, 27 April 2022 https://doi.org/10.3389/fpubh.2022.832444

Reedman CN, Drews SJ, Yi QL, Pambrun C, O’Brien SF. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era. Microbiology Spectrum. Le 12 avril 2022. doi : 10.1128/spectrum.00339-22

Bhatt M, Plint AC, Tang K, Malley R, Huy AP, McGahern C, Dawson J, Pelchat M, Dawson L, Varshney T, Arnold C, Galipeau Y, Austin M, Thampi N, Alnaji F, Langlois MA, Zemek RL. Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study. CMAJ Open. Avril 2020;10(2):E357-66. doi : 10.9778/cmajo.20220026.

Nasreen S, Febriani Y, Velásquez García HA, Zhang G, Tadrous M, Buchan SA, Righolt CH, Mahmoud SM, Janjua NZ, Krajden M, De Serres G, Kwong JC. Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study. medRxiv. 2022.04.13.22273825; doi : https://doi.org/10.1101/2022.04.13.22273825

McMillan B, Marquez AC, Gaultier GN, Bartlett SR, Skowronski D, Levings M, Steiner T, Zlosnik J, Krajden M, Morshed M, Sekirov I, Jassem AN, Sadarangani M. Prospective Evaluation of Immunity After COVID-19 Vaccines: The PREVENT-COVID Study.

Banerjee A, Lew J, Kroeker A, Baid K, Aftanas P, Nirmalarajah K, Maguire F, Kozak R, McDonald R, Lang A, Gerdts V, Straus SE, Gilbert L, Li AX, Mozafarihasjin M, Walmsley S, Gingras AC, Wrana JL, Mazzulli T, Colwill K, McGeer AJ, Mubareka S, Falzarano D. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants. Med. Le 13 avril 2022. doi : 10.1016/j.medj.2022.04.002

Nantel S, Bourdin B, Adams K, Carbonneau J, Rabezanaha H, Hamelin ME, McCormack D, Savard P, Longtin Y, Cheng M, DeSerres G, Corbeil J, Gilca V, Baz M, Boivin G, Quach C, Decaluwe H. Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection. medRxiv. Le 1er janvier 2022. doi : 10.1101/2022.03.29.22272714.

Hutchison SM, Watts A, Gadermann A, Oberle E, Oberlander TF, Lavoie PM, Mâsse LC. School staff and teachers during the second year of COVID-19: Higher anxiety symptoms, higher psychological distress, and poorer mental health compared to the general population. J Affect Disord. Le 17 mars 2022. doi : 10.1016/j.jadr.2022.100335.

Anand SS, Arnold C, Bangdiwala S, Bolotin S, Bowdish D, Chanchlani R, de Souza R, Desai D, Kandasamy S, Khan F, Khan Z, Langlois M-A, Limbachia J, Lear S, Loeb M, Loh L, Manoharan B, Nakka K, Pelchat M, Punthakee Z, Schulze K, Williams N, Wahi G. What factors converged to create a COVID-19 hot-spot? Lessons from the South Asian community in Ontario. medRxiv. Le 1er avril 2022. doi : 10.1101/2022.04.01.22273252.

Goldfarb DM, Mâsse LC, Watts AW, Hutchison SM, Muttucomaroe L, Bosman ES, Barakauskas VE, Choi A, Dhillon N, Irvine MA, Reicherz F, O’Reilly C, Sediqi S, Xu RY, Razzaghian HR, Sadarangani M, Coombs D, O’Brien SF, Lavoie PM. SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study. BMJ Open. Le 5 avril 2022. doi : 10.1136/bmjopen-2021-057846.

Jantzen R, Maltais M, Broët P. Socio-Demographic Factors Associated With COVID-19 Vaccine Hesitancy Among Middle-Aged Adults During the Quebec’s Vaccination Campaign. Front Public Health, le 18 mars 2022. https://doi.org/10.3389/fpubh.2022.756037

Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, Sprague AE, Buchan SA, Kwong JC, Wilson SE, Håberg SE, Gravel CA, Wilson K, El-Chaâr D, Walker MC, Barrett J, MacDonald SE, Okun N, Shah PS, Dougan SD, Dunn S, Bisnaire L. Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. JAMA. Publié en ligne le 24 mars 2022. doi : 10.1001/jama.2022.4255.

Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis A, Leung V, Holmes DT, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses. medRxiv. 2022.03.22.22272793; doi : https://doi.org/10.1101/2022.03.22.22272793.

Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, Abe KT, Wang JH, Pasculescu A, Maltseva M, Rocheleau L, Pelchat M, Fazel-Zarandi M, Iskilova M, Barrios-Rodiles M, Bennett L, Yau K, Cholette F, Mesa C, Li AX, Paterson A, Hladunewich MA, Goodwin PJ, Wrana JL, Drews SJ, Mubareka S, McGeer AJ, Kim J, Langlois MA, Gingras AC, Durocher Y. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunol. Le 23 mars 2022. doi : 10.1002/cti2.1380.

Nikiforuk AM, McMillan B, Bartlett SR, Márquez AC, Pidduck T, Kustra J, Goldfarb DM, Barakauskas V, Sinclair G, Patrick DM, Sadarangani M, Ogilvie GS, Krajden M, Morshed M, Sekirov I, Jassem AN. Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Detect a SARS-CoV-2 Antibody Response. Microbiol Spectr. Le 10 mars 2022:e0140521. doi : 10.1128/spectrum.01405-21.

Oliver MJ, Thomas D, Balamchi S, Ip J, Naylor K, Dixon SN, McArthur E, Kwong J, Perl J, Atiquzzaman M, Singer J, Yeung A, Hladunewich M, Yau K, Garg AX, Leis JA, Levin A, Krajden M, Blake PG. Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada. JASN Mars 2022, ASN.2021091262; doi : https://doi.org/10.1681/ASN.2021091262

Grunau B, Golding L, Prusinkiewicz MA, Asamoah-Boaheng M, Armour R, Citlali Marquez A, Jassem AN, Barakauskas V, O’Brien SF, Drews SJ, Haig S, Lavoie PM, Goldfarb DM. Comparative 6-month Wild-Type and Delta-Variant Antibody levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 vs. mRNA-1273. Microbiol Spectr Le 7 mars 2022:e0270221. doi: 10.1128/spectrum.02702-21.

Asamoah-Boaheng M, Goldfarb D, Prusinkiewicz M, Golding L, Karim M, Barakauskas V, Wall N, Jassem A, Marquez A, MacDonald C, O’Brien S, Lavoie P, Grunau B. Determining the optimal SARS-CoV-2 mRNA vaccine dosing interval for maximum immunogenicity. bioRxiv 2022.03.01.482592; doi : https://doi.org/10.1101/2022.03.01.482592

Walmsley S, Szadkowski L, Wouters B, Clarke R, Colwill K, Rochon P, Brudno M, Ravindran R, Raboud J, McGeer A, Oza A. Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study. medRxiv. Le 10 février 2022. doi : 10.1101/2022.02.09.22270734v1

Tang X, Sharma A, Pasic M, Brown P, Colwill K, Gelband H, Birnboim HC, Nagelkerke N, Bogoch II, Bansal A, Newcombe L, Slater J, Rodriguez PS, Huang G, Fu SH, Meh C, Wu CN, Kaul R, Langlois MA, Morawski E, Hollander A, Eliopoulos D, Aloi B, Lam T, Abe KT, Rathod B, Fazel-Zarandi M, Wang J, Iskilova M, Pasculescu A, Caldwell L, Barrios-Rodiles M, Mohammed-Ali Z, Vas N, Santhanam DR, Cho ER, Qu K, Jha S, Jha V, Suraweera W, Malhotra V, Mastali K, Wen R, Sinha S, Reid A, Gingras AC, Chakraborty P, Slutsky AS, Jha P. Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA Network Open. Le 16 février 2022;5(2):e2146798. doi : 10.1001/jamanetworkopen.2021.46798.

Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, Wilson K, Wilson SE, Kwong JC. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv 2021. doi : https://doi.org/10.1101/2021.12.30.21268565

Hall VG, Ferreira V, Ierullo M, Ku T, Majchrzak-Kita B, Kulasingam V, Humar A, Kumar D. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol (2022). doi : https://doi.org/10.1038/s41590-021-01126-6

Yau K, Chan CT, Abe KT, Jiang Y, Atiquzzaman M, Mullin SI, Shadowitz E, Liu L, Kostadinovic E, Sukovic T, Gonzalez A, McGrath-Chong ME, Oliver MJ, Perl J, Leis JA, Bolotin S, Tran V, Levin A, Blake PG, Colwill K, Gingras AC et Hladunewich MA. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. Le 3 février 2022;cmaj.211881; DOI : https://doi.org/10.1503/cmaj.211881

Ings DP, Hatfield KM, Fifield KE, Harnum DOA, Holder KA, Russell RS, Grant MD. Few SARS-CoV-2 infections detected in Newfoundland and Labrador in the absence of Public Health Laboratory-based confirmation. PLoS One. Le 28 janvier 2022;17(1):e0262957. doi : 10.1371/journal.pone.0262957.

Dayam RM, Law JC, Goetgebuer RL, Chao GYC, Abe KT, Sutton M, Finkelstein N, Stempak JM, Pereira D, Croitoru D, Acheampong L, Rizwan S, Rymaszewski K, Milgrom R, Ganatra D, Batista NV, Girard M, Lau I, Law R, Cheung MW, Rathod B, Kitaygorodsky J, Samson R, Hu Q, Haroon N, Inman RD, Piguet V, Chandran V, Silverberg MS, Gingras AC, Watts TH. Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases. medRxiv 2022.01.26.22269856; doi : https://doi.org/10.1101/2022.01.26.22269856

Widdifield J, Eder L, Chen S, Kwong JC, Hitchon C, Lacaille D, Aviña-Zubieta JA, Svenson LW, Bernatsky S. COVID-19 Vaccination Uptake among individuals with Immune-Mediated Inflammatory Diseases in Ontario, Canada between December 2020 and October 2021: A population-based analysis. J Rheumatol. Le 15 janvier 2022:jrheum.211148. doi : 10.3899/jrheum.211148.

Zhang A, Breznik JA, Clare R, Nazy I, Miller MS, Bowdish DME, Costa AP. Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents. J Am Med Dir Assoc. Le 15 janvier 2022:S1525-8610(21)01109-9. doi : 10.1016/j.jamda.2021.12.035.

Hall V, Ferreira V, Ierullo M, Ku T, Majchrzak-Kita B, Kulasingam V, Humar A, Kumar D. Delayed interval BNT162b2 mRNA COVID-19 vaccination provides robust immunity. 2021, Nature Immunology.

Nasreen S, Calzavara A, Buchan SA, Thampi N, Johnson C, Wilson SE, Kwong JC. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance. medRxiv. Le 16 janvier 2022. doi : 10.1101/2022.01.12.22269169.

Banerjee A, Lew J, Kroeker A, Baid K, Aftanas P, Nirmalarajah K, Maguire F, Kozak R, McDonald R, Lang A, Gerdts V, Straus SE, Gilbert L, Li AX, Mozafarihasjin M, Walmsley S, Gingras AC, Wrana JL, Mazzulli T, Colwill K, McGeer AJ, Mubareka S, Falzarano D. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants. bioRxiv. Le 13 janvier 2022. doi : 10.1101/2022.01.13.475409

Kronfi N, Dussault C, Maheu-Giroux M, Halavrezos A, Chalifoux S, Sherman J, Park, H, Del Balso L, Cheng MP, Poulin S, Cox J. Seroprevalence and Risk Factors for SARS-CoV-2 Among Incarcerated Adult Men in Quebec, Canada (2021), Clin Infect Dis, 2022; ciac031, https://doi.org/10.1093/cid/ciac031

Mwimanzi FM, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi HF, Burns L, Young L, Leung V, Ennis S, Agafitei O, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, DeMarco M, Holmes D., Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose. medRxiv. Le 6 janvier 2022. doi : 10.1101/2022.01.06.22268745

Zhang A, Breznik JA, Clare R, Nazy I, Miller MS, Bowdish DME, Costa AP. COVID-in-LTC Study Group. Antibody Responses to 3rd Dose mRNA Vaccines in Nursing Home and Assisted Living Residents. medRxiv, décembre 2021. doi : https://doi.org/10.1101/2021.12.17.21267996

Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay J, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, Wilson K, Wilson SE, Kwong J. Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv 2021. doi : https://doi.org/10.1101/2021.12.30.21268565

Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, Yan T, Cao C, Gurry C, Hankins CA, Cheng MP, Gingras AC, Mazer BD, Papenburg J, Langlois MA. Adapting serosurveys for the SARS-CoV-2 vaccine era. Open Forum Infect Dis, 2021; ofab632. doi : https://doi.org/10.1093/ofid/ofab632

Kim GN, Choi JA, Wu K, Saeedian N, Yang E, Park H, Woo SJ, Lim G, Kim SG, Eo SK, Jeong HW, Kim T, Chang JH, Seo SH, Kim NH, Choi E, Choo S, Lee S, Winterborn A, Li Y, Parham K, Donovan JM, Fenton B, Dikeakos JD, Dekaban GA, Haeryfar SMM, Troyer RM, Arts EJ, Barr SD, Song M, Kang CY. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathogens. Le 16 décembre 2021;17(12):e1010092. doi : 10.1371/journal.ppat.1010092

Nasreen S, Calzavara AJ, Sundaram ME, MacDonald SE, Righolt CH, Pai M, Field TS, Zhou LW, Wilson SE, Kwong JC. Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. BMJ Open 2021; 11:e052019. doi : 10.1136/bmjopen-2021-052019

Zinszer K, McKinnon B, Bourque N, Pierce L, Saucier A, Otis A, Cheriet I, Papenburg J, Hamelin ME, Charland K, Carbonneau J, Zahreddine M, Savard A, Fortin G, Apostolatos A, Haley N, Ratté N, Laurin I, Nguyen CT, Conrod P, Boivin G, De Serres G, Quach C; Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. JAMA Network Open 4.11 (2021):e2135975-e2135975.

Bergeri I, Whelan M, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X, Valenciano M, Cheng B, Al Ariqi L, Rashidian A, Okeibunor J, Azim T, Wijesinghe Le LV, Vaughan A, Pebody R, Vicari A, Yan T, Yanes-Lane M, Cao C, Cheng MP, Papenburg J, Buckeridge D, Bobrovitz N, Arora RK, van Kerkhove MD, Unity Studies Collaborator. Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021. GroupmedRxiv 2021.12.14.21267791; doi : https://doi.org/10.1101/2021.12.14.21267791

Cao H, Mai J, Zhou Z, Li Z, Duan R, Watt J, Chen Z, Bandara RA, Li M, Ahn SK, Poon B, Christie-Holmes N, Gray-Owen SD, Banerjee A, Mossman K, Kozak R, Mubareka S, Rini JM, Hu J, Liu J. Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell Biosci. Le 8 décembre 2021;11(1):202. doi: 10.1186/s13578-021-00723-0. PMID : 34879865; PMCID : PMC8653804.

Costiniuk CT, Singer J, Langlois M, Kulic I, Needham J, Burchell A, Jenabian M, Walmsley S, Ostrowski M, Kovacs C, Tan D, Harris M, Hull M, Brumme, Z, Brockman M, Margolese S, Mardarino E, Angel JB, Routy JP, Anis AH, Cooper C. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open 2021;11:e054208. doi : 10.1136/bmjopen-2021-054208

Law JC, Girard M, Chao GYC, Ward LA, Isho B, Rathod B, Colwill K, Li Z, Rini JM, Yue FY, Mubareka S, McGeer AJ, Ostrowski MA, Gommerman JL, Gingras A-C, Watts TH. Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. J Immunol. Le 13 décembre 2021. doi : 10.4049/jimmunol.2100727.

Cholette F, Mesa C, Harris A, Ellis H, Cachero K, Lacap P, Galipeau Y, Langlois M-A, Gingras A-C, Yansouni CP, Papenburg J, Cheng MP, Chakraborty P, Stein DR, Caeseele PV, Bartlett S, Krajden M, Goldfarb D, McGeer A, Osiowy C, Hankins C, Mazer B, Drebot M, Kim J, pour le compte du Groupe de travail sur l’immunité face à la COVID-19 (GTIC). Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. PLoS ONE. Le 7 décembre 2021. doi : 10.1371/journal.pone.0261003

Buchan SA, Yon Seo C, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu D, Harris TM, Yu K, Wilson SE. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. medRxiv. Le 5 décembre 2021. doi : https://doi.org/10.1101/2021.12.02.21267156

Bettinger JA, De Serres G, Valiquette L, Sadarangani M, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Isenor JE, McGeer A, Irvine M, Shulha H, Marty K. Canadian National Vaccine Safety (CANVAS) Network: Active Safety Surveillance on COVID-19 vaccines. Conférence canadienne sur l’immunisation. Le 8 décembre 2021.

Nasreen S, Calzavara A, Sundaram M, Macdonald SE, Righolt C, Pai M, Field T, Zhou LW, Wilson S, Kwong JC. Background rates of hospitalizations and emergency department visits for selected thromboembolic and coagulation disorders in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance. 2021. https://doi.org/10.1101/2021.04.02.21254856

Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung P, Ennis S, Ng K, Basra S, Lim LY, Yaseen F, Young L, Umviligihozo G, Omondi FH, Kalikawe R, Burns R, Brumme CJ, Leung V, Montaner JSG, Holmes D, DeMarco ML, Simons J, Pantophlet R, Niikura M, Romney MG, Brumme ZL. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis. Le 9 décembre 2021. doi : https://doi.org/10.1093/infdis/jiab592

Brunet-Ratnasingham E, Anand SP, Gantner P, Dyachenko A, Moquin-Beaudry G, Brassard N et coll. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Sci Adv. Le 26 novembre 2021;7(48):eabj5629. doi : 10.1126/sciadv.abj5629.

Grunau B, Goldfarb DM, Asamoah-Boaheng M, Golding L, Kirkham TL, Demers PA, Lavoie PM. Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals. JAMA. Le 3 décembre 2021. doi: 10.1001/jama.2021.21921

Galipeau Y, Siragam V, Laroche G, Marion E, Greig M, McGuinty M, Booth RA, Durocher Y, Cuperlovic-Culf M, Bennett SAL, Crawley AM, Giguère P, Cooper C, Langlois M-A. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine. Décembre 2021; doi : doi.org/10.1016/j.ebiom.2021.103700

Brunet-Ratnasingham E, Anand SP, Gantner P, Dyachenko A, Moquin-Beaudry G, Brassard N et coll. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Sci Adv. Le 26 novembre 2021;7(48):eabj5629. doi : 10.1126/sciadv.abj5629.

Bobrovitz N, Noel KC, Li Z, Cao C, Deveaux G, Selemon A, Lane MY, Yan T, Arora RK. SeroTracker-ROB: reproducible decision rules for risk of bias assessment of seroprevalence studies. doi : https://doi.org/10.1101/2021.11.17.21266471

Grunau B, Asamoah-Boaheng M, Lavoie PM, Ehsanul Karim M, Kirkham T, Demers PA, Barakauskas V, Citlali Marquez A, Jassem AN, O’Brien SF, Drews SJ, Haig S, Cheskes S, Goldfarb DM. A Higher Antibody Response is Generated with a 6 – 7 Week (vs Standard) SARS-CoV-2 Vaccine Dosing Interval. Clin Infect Dis. Novembre 2021;X(X):ZZ-XX. doi : 10.1093/cid/ciab938.

Ferreira VH, Marinelli T, Ierullo M, Ku T, Hall VG, Majchrzak-Kita B, Kulasingam V, Humar A, Kumar D. SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients. J Infect Dis. Le 5 novembre 2021. doi: 10.1093/infdis/jiab542.

Choi A, Mâsse LC, Bardwell S, Zhao Y, Xu YXZ, Markarian A, Coombs D, Watts A, Macdonald A, Dhillon N, Irvine M, O’Reilly C, Lavoie PM, Goldfarb D. Symptomatic and asymptomatic transmission of SARS-CoV-2 in K-12 schools, British Columbia, April to June 2021. medRxiv. Le 20 novembre 2021. doi.org/10.1101/2021.11.15.21266284

Shire ZJ, Reicherz F, Lawrence S, Sudan H, Golding L, Majdoubi A, Levett PN, Lavoie PM, Jacobson K. Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. Gut. Le 23 novembre 2021. doi : 10.1136/gutjnl-2021-326196

McKinnon B, Quach C, Dubé E, Nguyen CT, Zinszer K. Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada: a cross-sectional studyVaccinedoi: https://doi.org/10.1016/j.vaccine.2021.10.077

Kronfi N, Dussault C, Maheu-Giroux M, Halavrezos A, Chalifoux S, and Sherman J, Park, H, Del Balso L, Cheng MP, Poulin S, Cox J. Seroprevalence and Risk Factors for SARS-CoV-2 Among Incarcerated Adult Men in Quebec, Canada (2021): A Cross-Sectional Study. Pre-print The Lancet, November 9 2021 Doi: http://dx.doi.org/10.2139/ssrn.3959665

Breznik JA, Zhang A, Huynh A, Miller MS, Nazy I, Bowdish DME, Costa AP, Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents, JAMDA, DOI: https://doi.org/10.1016/j.jamda.2021.10.001

MacDonald C, Demers PA, Grunau B, Goldfarb D, O’Neill D, Armour R, Kirkham TL; Mental Health and Life Satisfaction Among Canadian Paramedics during the COVID-19 Pandemic.

Madathil S, Siqueira WL, Marin LM, Sanaulla FB, Faraj N, Quiñonez CR, et al. The incidence of COVID-19 among dentists practicing in the community in Canada: A prospective cohort study over a six-month period. The Journal of the American Dental Association. J Am Dent Assoc; 2021; DOI: https://doi.org/10.1016/j.adaj.2021.10.006

Fu Z, Rais, Y, Drabovich AP. Immunoprecipitation-targeted proteomics assays facilitate rational development of SARS-CoV-2 serological diagnostics. medRxiv. 25 Oct 2021. doi: 10.1101/2021.10.25.21265408v1

Drews SJ, Abe KT, Hu Q, Samson R, Gingras AC, Colwill K, Rathod B, Wang J, Fazel‐Zarandi M, Yi QL, Robinson A. Resistance of SARS‐CoV‐2 Beta and Gamma variants to plasma collected from Canadian blood donors during the Spring of 2020Transfusion. 2021 Oct 18. doi: 10.1111/trf.16713

Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, Abe KT, Wang JH, Pasculescu A, Maltseva M, Rocheleau L, Pelchat M, Fazel-Zarandi M, Iskilova M, Barrios-Rodiles M, Bennett L, Yau K, Cholette F, Mesa C, Li AX, Paterson A, Hladunewich MA, Goodwin PJ, Wrana JL, Drews SJ, Mubareka S, McGeer AJ, Kim J, Langlois M-A, Gingras A-C, Durocher Y. A “Made-in-Canada” serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccinationbioRxiv. 2021 Oct 26. doi: 10.1101/2021.10.25.21265476v1

Demone JJ, Maltseva M, Nourimand M, Nasr-Sharif M, Galipeau Y, Langlois MA, MacLean AM. Plant-based production of SARS-CoV-2 antigens for use in a subunit vaccine. bioRxiv. 2021 Jan 1. doi: 10.1101/2021.10.17.464700

Mithani SS, Bota AB, Zhu DT, Wilson K. A scoping review of global vaccine certificate solutions for COVID-19. Hum Vaccin Immunother. 2021 Oct 6.  doi:10.1080/21645515.2021.1969849

Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. Humoral immune responses to COVID-19 vaccination in people living with HIV on suppressive antiretroviral therapy. medRxiv. 2021 Oct 4. doi: https://doi.org/10.1101/2021.10.03.21264320

Merkley E, Loewen PJ. Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in CanadaJAMA Netw Open. 2021 Sep 1;4(9):e2126635. doi: 10.1001/jamanetworkopen.2021.26635

Saeed S, O’Brien SF, Abe K, Yi O, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras A-C, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLOS ONE. 2021 Sep 23. doi: https://doi.org/10.1371/journal.pone.0257743

Ayoubkhani D, Pawelek P, Gaughan C. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. UK Office for National Statistics. Released: 16 September 2021

SARS-CoV-2–Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals. J Immunol October 4, 2021, ji2100606; DOI: https://doi.org/10.4049/jimmunol.2100606

Antia R, Halloran ME. Transition to endemicity: Understanding COVID-19, Immunity (2021). Immunity, 24 september 2021 doi: 10.1016/j.immuni.2021.09.019

Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, Sengupta A, Brassard JP, Guerra A, Dziarmaga R, Perez A, Sun Y, Li Y, Roussel L, Langelier J, Ke D, Arnoldd C, Pelchat M, Langlois MA, Zhang X, Mazer BD. Real-world serologic responses to Extended-interval and Heterologous COVID-19 mRNA vaccination in Frail Elderly-Interim report from a prospective observational cohort study. medRxiv 21 Sept 2021; doi: 10.1101/2021.09.16.21263704

Luong L, Beder M, Nisenbaum R, Orkin A, Wong J, Damba C, Emond R, Lena S, Wright V, Loutfy M, Bruce-Barrett C, Cheung W, Cheung YK, Williams V, Vanmeurs M, Boozary A, Manning H, Hester J, Hwang SW, 2021. Prevalence of SARS-CoV-2 infection among people experiencing homelessness in Toronto during the first wave of the COVID-19 pandemic. medRxiv, September 26, 2021. doi:10.1101/2021.09.21.21263713

Saeed S, O’Brien SF, Abe K, Yi O, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras A-C, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLOS ONE. 2021 Sep 23. doi: https://doi.org/10.1371/journal.pone.0257743

Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Sbihi H, Fjell CD, Galanis E, Naus M, Patrick DM, El Adam S. Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada. medRxiv. 2021 Sept 22. doi : 10.1101/2021.09.20.21263875

Yanling Liu, Patrick Budylowski, Shilan Dong, Zhijie Li, Sofiya Goroshko, Leslie Y. T. Leung, Eyal Grunebaum, Paolo Campisi, Evan J. Propst, Nikolas E. Wolter, James M. Rini, Amin Zia, Mario Ostrowski and Götz R. A. Ehrhardt. SARS-CoV-2–Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals. J Immunol October 4, 2021, ji2100606; DOI: https://doi.org/10.4049/jimmunol.2100606

Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, Sengupta A, Brassard JP, Guerra A, Dziarmaga R, Perez A, Sun Y, Li Y, Roussel L, Langelier J, Ke D, Arnoldd C, Pelchat M, Langlois MA, Zhang X, Mazer BD. Real-world serologic responses to Extended-interval and Heterologous COVID-19 mRNA vaccination in Frail Elderly-Interim report from a prospective observational cohort study. medRxiv 21 Sept 2021;doi: 10.1101/2021.09.16.21263704

Saeed S, O’Brien SF, Abe K, Yi O, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras A-C, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. PLOS ONE. 2021 Sep 23. doi: https://doi.org/10.1371/journal.pone.0257743

Tang X, Gelband H, Nagelkerke N, Bogoch II, Brown P, Morawski E, Tam T. COVID-19 vaccination intention during early vaccine rollout in Canada: a nationwide online surveyThe Lancet Regional Health – Americas 2021:100055. doi : 10.1016/j.lana.2021.100055

Dick DW, Childs L, Feng Z, Li J, Röst G, Buckeridge DL, Ogden NH, Heffernan JM. Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada Modelling waning and boosting COVID-19 immunity in Canada A Canadian Immunization Research Network StudymedRxiv 2021.08.17.21262188; doi : 10.1101/2021.08.17.21262188

Hogan CA, Jassem AN, Sbihi H, Joffres Y, Tyson JR, Noftall K, Taylor M, Lee T, Fjell C, Wilmer A, Galbraith J, Romney MG, Henry B, Krajden M, Galanis E, Prystajecky N, Hoang LMN. Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021. Emerg Infect Dis. Le 13 août 2021;27(11). doi : 10.3201/eid2711.211190

Lee BE, Sikora C, Faulder D, Risling E, Little LA, Qiu Y, Gao T, Bulat R, Craik S, Hrudey SE, Ohinmaa A, Estabrooks C, Gingras AC, Charlton C, Kim J, Wood H, Robinson A, Kanji JN, Zelyas N, O’Brien SF, Drews S, Pang XL. Early Warning and Rapid Public Health Response to Prevent COVID-19 outbreaks in long-term care facilities (LTCF) by Monitoring SARS-CoV-2 RNA in LTCF site-specific Sewage Samples and Assessment of Antibodies Response in this Population – Prospective Study Protocol. BMJ Open Le 20 août 2021;11(8):e052282. doi : 10.1136/bmjopen-2021-052282.

Rais Y, Fu Z, Drabovich AP. Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. Clin Proteomics 2021;18:19. doi : 10.1186/s12014-021-09325-x

Tang X, Sharma A, Pasic M, Brown P, Colwill K, Gelband H, Birnboim HC, Nagelkerke N, Bogoch II, Bansal A, Newcombe L, Slater J, Rodriguez PS, Huang G, Fu SH, Meh C, Wu CN, Kaul R, Langlois MA, Morawski E, Hollander A, Eliopoulos D, Aloi B, Lam T, Abe KT, Rathod B, Fazel-Zarandi M, Wang J, Iskilova M, Pasculescu A, Caldwell L, Barrios-Rodiles M, Mohammed-Ali Z, Vas N, Santhanam DR, Cho ER, Qu K, Jha S, Jha V, Suraweera W, Malhotra V, Mastali K, Wen R, Sinha S, Reid A, Gingras AC, Chakraborty P, Slutsky AS, Jha P. SARS-CoV-2 Seroprevalence During the First and Second Pandemic Waves in Canada. Soc Sci Res Net. Le 12 août 2021. doi : http://dx.doi.org/10.2139/ssrn.3903944

Breznik JA, Zhang A, Huynh A, Miller MS, Nazy I, Bowdish DME, Costa AP, COVID in Long Term Care Study Group. Antibody responses 3-5 months post-vaccination with mRNA-1273 or BNT163b2 in nursing home residents. medRxiv. Le 19 août 2021. doi : https://doi.org/10.1101/2021.08.17.21262152

Abe KT, Hu Q, Mozafarihashjin M, Samson B, Rathod B, Chao G, Wang JH, Iskilova M, Pasculescu A, Fazel-Zarandi M, Li A, Paterson A, Green K, Gilbert L, Barati S, Haq N, Takaoka A, Takaoka JG, De Launay KQ, Fahim C, Sheikh-Mohamed S, Arita Y, Durocher Y, Marcusson EG, Gommerman JL, Ostrowski M, Colwill K, Straus SE, Wood H, McGeer AJ, Gingras AC. Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workersmedRxiv. Le 8 août 2021. doi : www.medrxiv.org/content/10.1101/2021.08.06.21261721v1

Sheikh-Mohamed S, Chao GYC, Isho B, Zuo M, Nahass GR, Salomon-Shulman RE, Blacker G, Fazel-Zarandi M, Rathod B, Colwill K, Jamal A, Li Z, Quin de Launay K, Takaoka A, Garnham-Takaoka J, Fahim C, Paterson A, Xinliu Li A, Haq N, Barati S, Gilbert L, Green K, Mozafarihashjin M, Samaan P, Siqueira W, Mubareka S, Ostrowski M, Rini JM, Rojas OL, McGeer A, Weissman IL, Caspi Tal M, Straus S, Gingras AC, Gommerman JL. A mucosal antibody response is induced by intra-muscular SARS-CoV-2 mRNA vaccination. medRxiv 2021.08.01.21261297; doi : https://doi.org/10.1101/2021.08.01.21261297

Nikiforuk AM, McMillan B, Bartlett SR, Márquez AC, Pidduck T, Kustra J, Goldfarb DM, Barakauskas V, Sinclair G, Patrick DM, Sadarangani M, Ogilvie GS, Morshed M, Sekirov, Jassem AN. Performance of Immunoglobulin G Serology on Finger Prick Capillary Dried Blood Spot Samples to Measure SARS-CoV-2 Seroconversion and Humoral Immunogenicity of COVID-19 Vaccination. medRxiv. Le 31 juillet 2021. doi : https://doi.org/10.1101/2021.07.29.21261156

Khana MS, Allison PJ, Siqueira WL, McNally ME, Glogauer M, Quinonez C, Madathil SA. Prevalence of COVID-19 among Canadian Dentists in August 2020. Affiche 1917, présentée à la 99e séance générale du congrès de l’Association internationale de recherches dentaires (AIRD). Du 21 au 24 juillet 2021.

Seth R, Allison PJ, Siqueira WL, McNally ME, Quinonez C, Glogauer M, Madathil SA. COVID-19 Anxiety syndrome among Canadian dentists during the pandemic. Affiche 1918, présentée à la 99e séance générale du congrès de l’Association internationale de recherches dentaires (AIRD). Du 21 au 24 juillet 2021.

Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B, Yousuf A, Kulasingam V, Humar A, Kumar D. Humoral and Cellular immune response and Safety of 2-dose SARS-CoV-2 mRNA-1273 (Moderna) vaccine in Solid Organ Transplant Recipients. Am J Transplant. date Juillet 2021 volume(number):pages. doi : link

Li X, Vanderloo LM, Maguire JL, Keown-Stoneman CDG, Aglipay M, Anderson LN, Cost KT, Charach A, Vanderhout SM, Birken CS, TARGet Kids! Collaboration, 2021. Public health preventive measures and child health behaviours during COVID-19: a cohort study. Can J Public Health. doi :10.17269/s41997-021-00549-w

Galipeau Y, Siragam V, Laroche G, Marion E, Greig M, McGuinty M, Booth RA, Durocher Y, Cuperlovic-Culf M, Bennett SAL, Crawley AM, Giguère P, Cooper C, Langlois M-A. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. MedRxiv 2021.07.16.21260079; doi : https://doi.org/10.1101/2021.07.16.21260079

McKinnon B, Quach C, Dubé E, Tuong Nguyen C, Zinszer K. Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada: a cross-sectional studydoi :https://doi.org/10.1101/2021.05.08.21256831

Williams C, Al-Bargash D, Macalintal C, Stuart R, Seth A, Latham J, Gitterman L, Fedsin S, Godoy M, Kozak R, Guthrie JL, Wood H, McGeer A, Hota S, Rea E. COVID-19 Outbreak Associated with a SARS-CoV-2 P. 1 Lineage in a Long-Term Care Home after Implementation of a Vaccination Program–Ontario, April-May 2021Clin Infect Dis. Le 8 juillet 2021. DOI : https://doi.org/10.1093/cid/ciab617

Duarte N, D’Mello S, Duarte NA, Rocco S, Wyk JV, Pillai AA, Liu M, Williamson T, Arora RK. Uptake of SARS-CoV-2 workplace testing programs, March 2020 to March 2021. medRxiv. Le 3 juillet 2021. doi: 10.1101/2021.06.29.21259730.

Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, Wilson SE, Sundaram ME, Fell DB, Chen B, Calzavara A, Austin PC, Schwartz KL, Tadrous M, Wilson K, Kwong JC. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv. Le 3 juillet 2021. doi: 10.1101/2021.06.28.21259420.

Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, Yanes-Lane M, Whelan M, Perlman-Arrow S, Chen J, Rahim H, Ilincic N, Segal M, Duarte N, Van Wyk J, Yan T, Atmaja A, Rocco S, Joseph A, Penny L, Clifton DA, Williamson T, Yansouni CP, Evans TG, Chevrier J, Papenburg J, Cheng MP. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. PLOS One. 16(6):e0252617. doi : 10.1371/journal.pone.0252617.

Law JC, Girard M, Chao GYC, Ward LA, Isho B, Rathod B, Colwill K, Li Z, Rini JM, Yue FY, Mubareka S, McGeer AJ, Ostrowski MA, Gommerman JL, Gingras AC, Watts TH. Immunity to SARS-CoV-2 persists 9 months post-symptoms with an altered T cell phenotype compared to influenza A virus-specific memory. medrxiv. Le 10 juin 2021. doi: 10.1101/2021.06.08.21258518.

Goldfarb DM, Mâsse LC, Watts AW, Hutchison SM, Muttucomaroe L, Bosman ES, Barakauskas VE, Choi A, Irvine MA, Reicherz F, Coombs D, O’Reilly C, Sediqi S, Razzaghian HR, Sadarangani M, O’Brien SF, Lavoie PM. SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada. medRxiv. Le 18 juin 2021. doi:10.1101/2021.06.16.21258861.

Kinloch NN, Ritchie G, Dong W, Cobarrubias KD, Sudderuddin H, Lawson T, Matic N, Montaner JSG, Leung V, Romney MG, Lowe CF, Brumme CJ, Brumme ZL. SARS-CoV-2 RNA quantification using droplet digital RT-PCRJ Mol Diagn. Le 29 mai 2021. doi : 10.1016/j.jmoldx.2021.04.014.

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta NE, Mahmud SM, Righolt CH, Svenson LW, Macdonald SE, Janjua NZ, Tadrous M, Kwong JC. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada. BMJ.doi : https://doi.org/10.1136/bmj.n1943 

Costa AP, Manis DR, Jones A, Stall NM, Brown KA, Boscard V, Castellino A, Heckman GA, Hillmer MP, Ma C, Pham P, Rais S, Sinha SK, Poss JW. Facteurs de risque d’éclosion de SRAS-CoV-2 dans les résidences pour aînés en Ontario, au Canada: étude de cohorte à l’échelle de la population. JAMC. Le 21 juin 2021;193(25):E969-77. doi: 10.1503/cmaj.202756-f.

Goldfarb DM, Mâsse LC, Watts AW, Hutchison SM, Muttucomaroe L, Bosman ES, Barakauskas VE, Choi A, Irvine MA, Reicherz F, Coombs D, O’Reilly C, Sediqi S, Razzaghian HR, Sadarangani M, O’Brien SF, Lavoie PM. SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada. medRxiv. Le 18 juin 2021. doi: 10.1101/2021.06.16.21258861.

Law JC, Girard M, Chao GYC, Ward LA, Isho B, Rathod B, Colwill K, Li Z, Rini JM, Yue FY, Mubareka S, McGeer AJ, Ostrowski MA, Gommerman JL, Gingras A-C, Watts TH. Immunity to SARS-CoV-2 persists 9 months post-symptoms with an altered T cell phenotype compared to influenza A virus-specific memory. medRxiv. Le 10 juin 2021. doi: 10.1101/2021.06.08.21258518.

Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, Young M, Dong W, Brumme ZL, Brumme CJ, Leung V, Romney MG. Rapid detection of SARS-CoV-2 variants of concern identifying a cluster of B.1.1.28/P.1 variant in British Columbia, Canada. Emerg Infect Dis. Le juin 2021;27(6):1673-1676. doi: 10.3201/eid2706.210532.

Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, Chen B, Calzavara A, Fell DB, Austin PC, Wilson K, Schwartz KL, Brown KA, Gubbay JB, Basta NE, Mahmud SM, Righolt CH, Svenson LW, Macdonald SE, Janjua NZ, Tadrous M, Kwong JC. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada. Le 28 mai 2021. doi: 10.1101/2021.05.24.21257744.

Saeed S, O’Brien SF, Abe K, Yi O, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras A-C, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. medRxiv. 2021 May 12. doi: 10.1101/2021.05.11.21256992.

Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, Brunet-Ratnasingham E, Medjahed E, Gendron-Lepage G, Goyette G, Gokool L, Morrisseau C, Bégin P, Martel-Laferrière V, Tremblay C, Richard J, Bazin R, Duerr R, Kaufmann D, Finzi A.  Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. Le 4 mai 2021. doi: 10.1016/j.xcrm.2021.100290.

Tang X, Gelband H, Nagelkerke N, Bogoch I, Brown PE, Morawski E, Lam T, Reid A, Jha P. Quantifying COVID-19 vaccination hesitancy during early vaccination rollout in Canada. medRxiv [Preprint]. Le 2 mai 2021. doi: 10.1101/2021.04.29.21256333.

Flood CM, Thomas B, Wilson K. Vaccination obligatoire des travailleurs de la santé: analyse juridique et politique. CMAJ. Le 26 avril 2021 Avr. 26;193(17):E629-33. doi: 10.1503/cmaj.202755-f.

Huynh A, Arnold DM, Smith JW, Moore JC, Zhang A, Chagla Z, Harvey BJ, Stacey HD, Ang JC, Clare R, Ivetic N, Chetty VT, Bowdish DME, Miller MS, Kelton JG, Nazy I. Characteristics of anti-SARS-CoV-2 antibodies in recovered COVID-19 subjects. Viruses. Le 16 avril 2021. 16;13(4):697. doi: 10.3390/v13040697.

Zinszer K, McKinnon B, Bourque N, Zahreddine M, Charland K, Papenburg J, Fortin G, Hamelin ME, Saucier A, Apostolatos A, Pierce L, Savard-Lamothe A, Carbonneau J, Conrod P, Haley N, Laurin I, Boivin G, Serres GD, Quach C. Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: Protocol for a cohort study in Montreal, Canada. medRxiv [Preprint]. Le 16 avril 2021. doi: 10.1101/2021.04.14.21255499.

Brockman MA, Mwimanzi F, Sang Y, Ng K, Agafitei O, Ennis S, Lapointe H, Young L, Umviligihozo G, Burns L, Brumme CJ, Leung V, Montaner JSG, Holmes D, DeMarco M, Simons J, Niikura M, Pantophlet R, Romney MG, Brumme ZL. Weak humoral immune reactivity among elderly residents of long-term care facilities following one dose of BNT162b2 mRNA COVID-19 vaccine. medRxiv [Preprint]. Le 24 mars 2021. doi: 10.1101/2021.03.17.21253773

Irfan Ullah, Jérémie Prévost, Mark S Ladinsky, Helen Stone, Maolin Lu, Sai Priya Anand, Guillaume Beaudoin-Bussières, Mehdi Benlarbi, Shilei Ding, Romain Gasser, Corby Fink, Yaozong Chen, Alexandra Tauzin, Guillaume Goyette, Catherine Bourassa, Halima Medjahed, Matthias Mack, Kunho Chung, Craig B Wilen, Gregory A. Dekaban, Jimmy D. Dikeakos, Emily A. Bruce, Daniel E Kaufmann, Leonidas Stamatatos, Andrew T. McGuire, Jonathan Richard, Marzena Pazgier, Pamela J. Bjorkman, Walther Mothes, Andrés Finzi, Priti Kumar, Pradeep D. Uchil. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. bioRxiv [Preprint]. Le 22 mars 2021. doi: 10.1101/2021.03.22.436337

Brunet-Ratnasingham E, Anand SP, Gantner P, Moquin-Beaudry G, Dyachenko A, Brassard N, Beaudoin-Bussières G, Pagliuzza A, Gasser R, Benlarbi M, Point F, Prévost J, Laumaea A, Niessl J, Nayrac M, Sannier G, Boutin M, Descôteux-Dinelle J, Gendron-Lepage G, Goyette G, Bourassa C, Medjahed H, Orban C, Butler-Laporte G, Morrison D, Zhou S, Nakanishi T, Laurent L, Richard J, Dubé M, Fromentin R, Rébillard R-M, Arbour N, Prat A, Larochelle C, Durand M, Richards JB, Chassé M, Tétreault M, Chomont N, Finzi A, Kaufmann DE. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. medRxiv [Preprint]. Le 20 mars 2021. doi: 10.1101/2021.03.18.21253907

Majdoubi A, Michalski C, O’Connell SE, Dada S, Narpala S, Gelinas J, Mehta D, Cheung C, Winkler D, Basappa M, Liu  AC, Görges M, Barakauska VE, Irvine M, Mehalko J, Esposito D, Sekirov I, Jassem AN, Goldfarb DM, Pelech S, Douek DC, McDermott AB, Lavoie PM. A majority of uninfected adults show pre-existing antibody reactivity against SARS-CoV-2. JCI Insight. Le 15 mars 2021. doi: 10.1172/jci.insight.146316.

Castonguay N, Zhang W, Langlois M-A. Meta-analysis of the dynamics of the emergence of mutations and variants of SARS-CoV-2. medRxiv [Preprint]. Le 8 mars 2021. doi: 10.1101/2021.03.06.21252994

Tang X, Sharma A, Pasic M, Colwill K, Birnboim Ch, Nagelkerke Nico, Bogoch I, Schultz C, Newcombe L, Slater J, Rodriguez P, Huang G, Fu SH,  Meh C, Wu ChN,  Kaul R, Langlois MA, M E, Hollander A, Eliopoulos D, Aloi B, Lambe T, AbeK, Caldwell L, Barrios-Rodiles M,  Fazel-Zarandi M, Weingust R, Wang J, Rathod B, Santhanam DR, Cho ER, Qu K, Jha S, Jha V, Suraweera W,  Wen R, Sinha SR, Gingras AC, Chakraborty P, Slutsky  AS, Jha P. COVID symptoms, seroprevalence, and mortality during the first wave of SARS-CoV-2 in Canada. medRxiv [Preprint]. Le 5 mars 2021. doi: 10.1101/2021.03.04.21252540.

K Wilson and C Flood. Implementing digital passports for SARS-CoV-2 immunization in Canada. CMAJ. Le 2 mars 2021;193(10). doi: 10.1503/cmaj.210244.

Rébillard RM, Charabati M, Grasmuck C, Filali-Mouhim A, Tastet O, Brassard N, Daigneault A, Bourbonnière L, Anand SP, Balthazard R, Beaudoin-Bussières G, Gasser R, Benlarbi M, Carmena Moratalla A, Carpentier Solorio Y, Boutin M, Farzam-Kia N, Descôteaux-Dinelle J, Fournier AP, Gowing EM, Laumaea A, Jamann H, Lahav B, Goyette G, Lemaître F, Mamane VH, Prévost J, Richard J, Thai K, Cailhier JF, Chomont N, Finzi A, Chassé M, Durand M, Arbour N, Kaufmann DE, Prat A, Larochelle C. Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. J Clin Invest. Le 26 février 2021;26:145853. doi: 10.1172/JCI145853

Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kelton JG, Arnold DM. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost. Le 27 février 2021. doi: 10.1111/jth.15283.

Papenburg J , Cheng MP , Corsini R, Caya C, Mendoza E, Manguiat K, Lindsay LF , Wood H, Drebot MA, Dibernardo A , Zaharatos G , Bazin R, Gasser R, Benlarbi M , Gendron-Lepage G, Beaudoin-Bussières G, Prévost J, Finzi A, Ndao M, Yansouni C.  Evaluation of a commercial culture-free neutralization antibody detection kit for severe acute respiratory syndrome-related coronavirus-2 and comparison with an anti-RBD ELISA assay. medRxiv [Preprint]. Le 20 février 2021. doi: 10.1101/2021.01.23.21250325.

Anand SP, Prévost J, Richard J, Perreault J, Tremblay T, Drouin M, Fournier MJ, Lewin A, Bazin R, Finzi A. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. Transfusion. Le 18 février 2021. doi: 10.1111/trf.16318.

Gasser R, Cloutier M, Prévost J, Fink C, Ducas É, Ding S, Dussault N, Landry P, Tremblay T, Laforce-Lavoie A, Lewin A, Beaudoin-Bussières G, Laumaea A, Medjahed H, Larochelle C, Richard J, Dekaban GA, Dikeakos JD, Bazin R, Finzi A. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep. Le février 2021. 10:108790. doi: 10.1016/j.celrep.2021.108790.

Flood C, Thomas B, Wilson K. Mandatory vaccination for health care workers: an analysis of law and policy. CMAJ. Le 8 février 2021. 8;193(6). doi.org/10.1503/cmaj.202755.

Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O’Brien SF. SARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada. Transfusion. Le 1 février 2021. doi: 10.1111/trf.16296.

Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, Deeks SL, Allen VG. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. J Infect Dis. Le 5 janvier 2021:jiaa796. doi: 10.1093/infdis/jiaa796.

Law JC, Koh WH, Budylowski P, Lin J, Yue F, Abe KT, Rathod B, Girard M, Li Z, Rini JM, Mubareka S, McGeer A, Chan AK, Gingras AC, Watts TH, A Ostrowski M. Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile. J Immunol. Le 1 janvier 2021;206(1):37-50. doi: 10.4049/jimmunol.2001067.

Lu M, Uchil PD, Li W, Zheng D, Terry DS, Gorman J, Shi W, Zhang B, Zhou T, Ding S, Gasser R, Prévost J, Beaudoin-Bussières G, Anand SP, Laumaea A, Grover JR, Liu L, Ho DD, Mascola JR, Finzi A, Kwong PD, Blanchard SC, Mothes W. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. Cell Host & Microbe. Le 9 décembre 2020;28(6):880-891. doi: 0.1016/j.chom.2020.11.001.

Ding S, Laumaea A, Benlarbi M, Beaudoin-Bussières G, Gasser R, Medjahed H, Pancera M, Stamatatos L, McGuire AT, Bazin R, Finzi A. Antibody binding to SARS-CoV-2 S glycoprotein correlates with but does not predict neutralization. Viruses. Le 26 octobre 2020; 12(11):1214. doi: 10.3390/v12111214.

Prévost J, Gasser R, Beaudoin-Bussières G, Richard J, Duerr R, Laumaea A, Anand SP, Goyette G, Benlarbi M, Ding S, Medjahed H, Lewin A, Perreault J, Tremblay T, Gendron-Lepage G, Gauthier N, Carrier M, Marcoux D, Piché A, Lavoie M, Benoit A, Loungnarath V, Brochu G, Haddad E, Stacey HD, Miller MS, Desforges M, Talbot PJ, Maule GTG, Côté M, Therrien C, Serhir B, Bazin R, Roger M, Finzi A. Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike. Cell Rep Med. Le 20 octobre 2020;1(7):100126. doi: 10.1016/j.xcrm.2020.100126.

Beaudoin-Bussières G, Laumaea A, Anand SP, Prévost J, Gasser R, Goyette G, Medjahed H, Perreault J, Tremblay T, Lewin A, Gokool L, Morrisseau C, Bégin P, Tremblay C, Martel-Laferrière V, Kaufmann D, Richard J, Bazin R, Finzi A. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio. Le 16 octobre 2020. doi: 10.1128/mBio.02590-20.

Anand SP, Chen Y, Prévost J, Gasser R, Beaudoin-Bussières G, Abrams CF, Pazgier M, Finzi A. Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins. Viruses. Le 29 septembre 2020;12(10):1104. doi: 10.3390/v12101104.

Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, Yan T, Bobrovitz N, Chevrier J, Cheng MP, Williamson T. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis. Le aout 2020. doi: 10.1016/S1473-3099(20)30631-9

Publications de nos experts

Stephen B. Freedman and James D. Kellner. Protecting Canada’s children from the consequences of the fourth wave of the COVID-19 pandemic. CMAJ September 27, 2021 193 (38) E1500-E1502; DOI: https://www.cmaj.ca/content/193/38/E1500

Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, Haerynck F, Cicalese MP, Hagin D, Soler-Palacín P, Planas AM. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. Journal of Clinical Immunology. 2021 Jun 8:1-8.

Yang J, D’Souza R, Kharrat A, Fell DB, Snelgrove JW, Murphy KE, Shah P.. COVID‐19 pandemic and population‐level pregnancy and neonatal outcomes: a living systematic review and meta‐analysisActa Obstet et Gynecol Scand 2021;100:1756–70. doi:10.1111/aogs.14206

Drouin O, Moore Hepburn C, Farrar DS, Baerg K, Chan K, Cyr C, Donner EJ, Embree JE, Farrell C, Forgie S, Giroux R, Kang KT, King M, Laffin M, Luu TM, Orkin J, Papenburg J, Pound CM, Price VE, Purewal R, Sadarangani M, Salvadori MI, Top KA, Viel-Thériault I, Kakkar F et Morris SK. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020CMAJ September 27, 2021 193 (38) E1483-E1493; DOI: https://www.cmaj.ca/content/193/38/E1483

Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Sbihi H, Fjell CD, Galanis E, Naus M, Patrick DM, El Adam S. Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, CanadamedRxiv. 2021 Sept 22. doi : 10.1101/2021.09.20.21263875

Luong L, Beder M, Nisenbaum R, Orkin A, Wong J, Damba C, Emond R, Lena S, Wright V, Loutfy M, Bruce-Barrett C, Cheung W, Cheung YK, Williams V, Vanmeurs M, Boozary A, Manning H, Hester J, Hwang SW, 2021. Prevalence of SARS-CoV-2 infection among people experiencing homelessness in Toronto during the first wave of the COVID-19 pandemic. medRxiv, September 26, 2021. doi:10.1101/2021.09.21.21263713

Top KA, Bettinger JA, Kwong JC, Wilson SE, Hapuhennedige S. Enhancing Canada’s Vaccine Safety Surveillance for COVID-19 Vaccination Programs. CANvax. 2021 Sep 8. https://canvax.ca/brief/enhancing-canadas-vaccine-safety-surveillance-covid-19-vaccination-programs / Top KA, Bettinger JA, Kwong JC, Wilson SE, Hapuhennedige S. Renforcement de la surveillance de l’innocuité des vaccins dans les programmes de vaccination contre la COVID-19 au Canada. CANvax. 2021 Sep 8. https://canvax.ca/fr/brief/renforcement-de-la-surveillance-de-linnocuite-des-vaccins-dans-les-programmes-de-vaccination

Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, Biggerstaff B, Crews BO, Tran N, Jerome KR, Denny TN, Hogema B, Destree M, Jones JM, Thornburg N, Simmons G, Krajden M, Kleinman S, Dumont LJ, Busch MP. Evaluation of commercially available high-throughput SARS-CoV-2 serological assays for serosurveillance and related applications. medRxiv doi: 10.1101/2021.09.04.21262414

Savitz DA, Bengtson AM, Hardy E, Fell DB. Pregnancy and the Risk of Severe COVID-19 Infection: Methodologic Challenges and Research Recommendations. BJOG. 18 Sep 2021. doi: 10.1111/1471-0528.16935.

Velásquez García HA, Wilton J, Smolina K, Chong M, Rasali D, Otterstatter M, Rose C, Prystajecky N, David S, Galanis E, McKee G, Krajden M, Zafar Janjua NZ. Mental health and substance use associated with hospitalization among people with laboratory confirmed diagnosis of COVID-19 in British Columbia: a population-based cohort study. medRxiv. Le 28 août 2021. doi : 10.1101/2021.08.26.21262697

Kaida A, Brotto LA, Murray MCM, Cote HCF, Albert AY, Nicholson V, Gormley R, Gordon S, Booth A, Smith LW, Baaske A, Galea LAM, Sadarangani M, Ogilvie GS. Intention to receive a COVID-19 vaccine by HIV status among a population-based sample of women and gender diverse individuals in British Columbia, Canada. Le 22 août 2021. https://www.medrxiv.org/content/10.1101/2021.08.19.21262249v1 doi : https://doi.org/10.1101/2021.08.19.21262249

Bastard P, …, [Vinh DC] …, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsSci Immunol. Le 19 août 2021;6(62):eabl4340. doi : 10.1126/sciimmunol.abl4340. PMID : 34413139.

Fisman DN, Greer AL, Brankston G, Hillmer M, O’Brien SF, Drews SJ, Tuite AR. COVID-19 Case Age Distribution: Correction for Differential Testing by Age. Ann Intern Med. doi : 10.7326/M20-7003

Sundaram M, Nasreen S, Calzavara A, He S, Chung H, Bronskill SE, Buchan SA, Tadrous M, Tanuseputro P, Wilson W, Wilson S, Kwong JC. Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments. Vaccine. 2021;39:5265-70. doi : https://doi.org/10.1016/j.vaccine.2021.07.060

Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, Trottier B, Richard J, Durand M, Kaufmann D, Finzi A, Tremblay C. Covid-19 vaccine immunogenicity in people living with HIV-1. bioRxiv 2021.08.13.456258. doi : https://doi.org/10.1101/2021.08.13.456258

Gobeil PA, Pillet S, Boulay I, Charland N, Lorin A, Cheng M, Vinh D, Boutet P, Van Der Most R, Roman F, Perez MAC, D’Aoust MA, Landry N, Ward BJ. Durability and Cross-Reactivity of Immune Responses Induced by an AS03 Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19. medRxiv. Le 1er janvier 2021. doi : 10.1101/2021.08.04.21261507

Groves H, Piché‐Renaud PP, Allen U. The significance and impact of SARS‐CoV‐2 variants of concern in pediatric solid organ transplantation: More unknowns than knownsPediatr Transplant. Le 16 juin 2021. doi : 10.1111/petr.14071

Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, Selzner N, Schiff J, McDonald M, Tomlinson G, Kulasingam V, Kumar D, Humar A. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med, le 11 août 2021. doi : 10.1056/NEJMc2111462.

Parotto M, Nainan MS, Munblit D, Elhazmi A, Ranzani O, Herridge M. Recovery after prolonged ICU treatment in patients with COVID-1. Lancet Respir Med 2021;9(8):812-4. doi : https://doi.org/10.1016/S2213-2600(21)00318-0

Lewin A, Therrien R, De Serres G, Grégoire Y, Perreault J, Drouin M, Fournier M J, Tremblay T, Beaudoin J, Beaudoin-Bussières G, Prévost J, Gendron-Lepage G, Finzi A, Bernier F, Bazin R, Germain M, Delage G. (2021). SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study. Can J Public Health;112(4) :576–86. https://doi.org/10.17269/s41997-021-00531-6

Xia Y, Ma H, Moloney G, Velásquez García HA, Sirski M, Janjua NZ, Vickers D, Williamson T, Katz A, Yu K, Kustra R, Buckeridge DL, Brisson M, Baral SD, Mishra S, Maheu-Giroux M, 2021. Geographical concentration of COVID-19 cases by social determinants of health in 16 large metropolitan areas in Canada – a cross-sectional study. medRxiv. 2021.07.23.21261039; doi : 10.1101/2021.07.23.21261039

Nourbakhsh S, Fazil A, Li M, Mangat CS, Peterson SW, Daigle J, Langner S, Shurgold J, D’Aoust P, Delatolla R, Mercier E, Pang X, Lee BE, Stuart R, Wijayasri S, Champredon D. A Wastewater-based epidemic model for SARS-CoV-2 with application to three Canadian cities. medRxiv. Le 25 juillet 2021. doi : https://doi.org/10.1101/2021.07.19.21260773

Wilson K, Sher G, Philpott J. Preparing for the next pandemic by creating Canadian Immunization Services. CMAJ 2021;193:E1092–3. doi : 10.1503/cmaj.210670; www.cmaj.ca/content/193/28/E1092

Bolotin S, Wilson S, Murti M. Achieving and sustaining herd immunity to SARS-CoV-2CMAJ Juillet 2021;193(28):E1089; DOI : 10.1503/cmaj.210892

Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia. Nature (2021). https://doi.org/10.1038/s41586-021-03744-4

Racey CS, Donken R, Porter I, Albert A, Bettinger JA, Mark J, Bonifacio L, Dawar M, Gagel M, Kling R, Mema S, Mitchell H, Roe I, Ogilvie G, Sadarangani M, 2021. Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccineVaccine: X 8, 100106. doi : 10.1016/j.jvacx.2021.100106

The CONCOR-1 Study Group, CONCOR-1 writing committee, Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, Zeller MP, Beaudoin-Bussières G, Amorim L, Bazin R, Loftsgard KC, Carl R, Chassé M, Cushing MM, Daneman N, Devine DV, Dumaresq J, Fergusson DA, Gabe C, Glesby MJ, Li N, Liu Y, McGeer A, Robitaille N, Sachais BS, Scales DC, Schwartz L, Shehata N, Turgeon AF, Wood H, Zarychanski R, Finzi A, Arnold DM, for The CONCOR-1 Study Group. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. medRxiv. Le 3 juillet 2021. doi: 10.1101/2021.06.29.21259427.

Abdulnoor M, Eshaghi A, Perusini SJ, Corbeil A, Cronin K, Fittipaldi N, Forbes JD, Guthrie JL, Kus JV, Majury A, Mazzulli T, Melano RG, Olsha R, Sullivan S, Tran V, Patel SN, Allen VG, Gubbay JB. Real-time RT-PCR allelic discrimination assay for detection of N501Y mutation in the spike protein of SARS-CoV-2 associated with variants of concern. medRxiv. Le 2 juillet 2021. doi: 10.1101/2021.06.23.21258782.

Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. Le 1 juillet 2021. doi: 10.1038/s41577-021-00578-z.

Zhang Y, Malekjahani A, Udugama BN, Kadhiresan P, Chen H, Osborne M, Franz M, Kucera M, Plenderleith S, Yip L, Bader GD, Tran V, Gubbay JB, McGeer A, Mubareka S, Chan WCW. Surveilling and tracking COVID-19 patients using a portable quantum dot smartphone device. Nano Lett. Le 23 juin 2021;21(12):5209-5216. doi: 10.1021/acs.nanolett.1c01280.

Bennet SMP, Kaufmann M, Takami K, Sjaarda C, Douchant K, Moslinger E, Wong H, Reed DE, Ellis AK, Vanner S, Colautti RI, Sheth PM. Small-molecule metabolome identifies potential therapeutic targets against COVID-19. medRxiv. Le 18 juin 2021. doi: 10.1101/2021.06.18.21259150.

Greenhawt M, Abrams EM, Shaker M, Chu DK, Kahn D, Akin C, Alqurashi W, Arkwright P, Baldwin JL, Ben-Shoshan M, Bernstein J, Bingeman T, Blumchen K, Byrne A, Bognanni A, Campbell D, Campbell R, Chagla Z, Chan ES, Chan J, Comberiatti P, Dribin TE, Ellis AK, Fleischer DM, Fox A, Frischmeyer-Guerrerio PA, Gagnon R, Grayson MH, Horner CC, Hourihane J, Katelaris CH, Kim H, Kelso JM, Lang D, Ledford D, Levin M, Lieberman J, Loh R, Mack D, Mazer B, Mosnaim G, Munblit D, Mustafa SS, Nanda A, Oppenheimer J, Perrett KP, Ramsey A, Rank M, Robertson K, Shiek J, Spergel JM, Stukus D, Tang MLK, Tracy JM, Turner PJ, Whalen-Browne A, Wallace D, Wang J, Wasserman S, Witty JK, Worm M, Vander Leek TK, Golden DBK. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: A systematic review, meta-analysis, GRADE assessment, and international consensus approach. J. Allergy Clin. Immunol. Le 18 juin 2021. doi: 10.1016/j.jaip.2021.06.006.

Griffin BD, Chan M, Tailor N, Mendoza EJ, Leung A, Warner BM, Duggan AT, Moffat E, He S, Garnett J, Tran KN, Banadyga L, Albietz A, Tierney K, Audet J, Bello A, Vendramelli R, Boese AS, Fernando L, Lindsay LR, Jardine CM, Wood H, Poliquin G, Strong JE, Drebot M, Safronetz D, Embury-Hyat C, Kobasa D. SARS-CoV-2 infection and transmission in the North American deer mouse. Nat Commun. Le 14 juin 2021;12:3612. doi: 10.1038/s41467-021-23848-9.

Brotto LA, Chankasingh K, Baaske A, Albert A, Booth A, Kaida A, Smith LW, Racey S, Gottschlich A, Murray MCM, Sadarangani M, Ogilvie GS, Galea L. The influence of sex, gender, age, and ethnicity on psychosocial factors and substance use throughout phases of the COVID-19 pandemic. medRxiv. Le 10 juin 2021. doi: 10.1101/2021.06.08.21258572.

Skowronski DM, Setayeshgar S, Zou M, Prystajecky N, Tyson JR, Galanis E, Naus M, Patrick DM, Sbihi H, El Adam S, Henry B, Hoang LMN, Sadarangani M, Jassem AN, Krajden M. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P. 1 and B. 1.1. 7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada. medRxiv. Le 9 juin 2021. doi: 10.1101/2021.06.07.21258332.

Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T, Shrum JM, Al Maqrashi ZAA, Shroff A, Lessard M-C, Blais N, Kelton JG, Nazy I. Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia. N Engl J Med. Le 9 juin 2021. doi: 10.1056/NEJMoa2107051.

Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, Haerynck F, Cicalese MP, Hagin D, Soler-Palacín P, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova JL, Meyts I; COVID Human Genetic Effort. Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J Clin Immunol. Le 8 juin 2021:1–18. doi: 10.1007/s10875-021-01068-6.

Verma AA, Hora T, Jung HY, Fralick M, Malecki SL, Lapointe-Shaw L, Weinerman A, Tang T, Kwan JL, Liu JJ, Rawal S, Chan TCY, Cheung AM, Rosella LC, Ghassemi M, Herridge M, Mamdani M, Razak F. Caractéristiques et issues des hospitalisations pour les cas de COVID-19 et d’influenza dans la région de Toronto. CMAJ. Le 7 juin 2021;193(23):E859-E869. doi: 10.1503/cmaj.202795-f.

Bullard J, Funk D, Dust K, Garnett L, Tran K, Bello A, Strong JE, Lee SJ, Waruk J, Hedley A, Alexander D, Caeseele PV, Loeppky C, Poliquin G. Comparison de l’infectivité du coronavirus du syndrome respiratoire aigu sévère 2 chez les enfants et les adultes. CMAJ. Le 7 juin 2021;193(23):E870-E877. doi: 10.1503/cmaj.210263-f.

Liu M, Arora RK, Krajden M. Tests de détection rapides d’antigènes pour le SRAS-CoV-2. CMAJ. Le 7 juin 2021;193(23):E886-E887. doi: 10.1503/cmaj.202827-f.

Reyes Domingo F, Waddell LA, Cheung AM, Cooper CL, Belcourt VJ, Zuckermann AME, Corrin T, Ahmad R, Boland L, Laprise C, Idzerda L, Khan A, Jaramillo Garcia A. Prevalence of long-term effects in individuals diagnosed with COVID-19: a living systematic review. Le 6 juin 2021. doi:10.1101/2021.06.03.21258317.

Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, Brassard N, Laumaea A, Vézina D, Prévost J, Anand SP, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Niessl J, Tastet O, Gokool L, Morrisseau C, Arlotto P, Stamatatos L, McGuire AT, Larochelle C, Uchil P, Lu M, Mothes W, De Serres G, Moreira S, Roger M, Richard J, Martel-Laferrière V, Duerr R, Tremblay C, Kaufmann DE, Finzi A. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses. Cell Host and Microbe. Le 4 juin 2021. doi: 10.1016/j.chom.2021.06.001.

Betti M, Bragazzi N, Heffernan J, Kong J, Raad A. Could a new COVID-19 mutant strain undermine vaccination efforts? A mathematical modelling approach for estimating the spread of B.1.1.7 using Ontario, Canada, as a case study. Vaccines. Le 3 juin 2021; 9(6):592. doi: 10.3390/vaccines9060592.

Heckman GA, Kay K, Morrison A, Grabowski DC, Hirdes JP, Mor V, Shaw G, Benjamin S, Boscart VM, Costa AP, Declercq A, Geffen L, Sang Lum TY, Moser A, Onder G, Van Hout H. Proceedings from an international virtual townhall: Reflecting on the COVID-19 pandemic: themes from long-term care. J Am Med Dir Assoc. Le 1 juin 2021. doi: 10.1016/j.jamda.2021.03.029.

Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, Gunaratnam L, Lamarche C, Tom A, Finzi A, Suri RS. Short-term antibody response afer 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ. Le 31 mai 2021. doi: 10.1503/cmaj.210673.

Ogilvie GS, Gordon S, Smith LW, Albert A, Racey CS, Booth A, Gottschlich A, Goldfarb D, Murray MCM, Galea LAM, Kaida A, Brotto LA, Sadarangani M. Intention to receive a COVID-19 vaccine: results from a population-based survey in Canada. BMC Public Health. Le 29 mai 2021;21(1):1017. doi: 10.1186/s12889-021-11098-9.

Wong ST, Romney M, Matic N, Haase K, Ranger M, Dhari R, Affleck F, Tan E, Ndateba I, Tobias E, Saewyc E, Schwandt M, Sin D. Feasibility and utility of rapid antigen testing for COVID-19 in a university residence: a cross sectional study. medRxiv. Le 26 mai 2021. doi: 10.1101/2021.05.24.21257732.

Verma AA, Pai M, Saha S, Bean S, Fralick M, Gibson JL, Greenberg RA, Kwan JL, Lapointe-Shaw L, Tang T, Morris AM, Razak F. Managing drug shortages during a pandemic: tocilizumab and COVID-19. CMAJ. Le 25 mai 2021;193(21):E771-E776. doi: 10.1503/cmaj.210531.

Yau K, Abe KT, Naimark D, Oliver MJ, Perl J, Leis JA, Bolotin S, Tran V, Mullin S, Shadowitz E, Garnham-Takaoka J, de Launay KQ, Takaoka A, Straus SE, McGeer AJ, Chan CT, Colwill K, Gingras A-C, Hladunewich MA. The humoral response to the BNT162b2 vaccine in hemodialysis patients.

Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, Giovannini-Chami L, Wood N, Chandler RE, Klein NP, Schlaudecker EP, Poli MC, Muscal E, Munoz FM. Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. Le 21 mai 2021;39(22):3037-3049. doi: 10.1016/j.vaccine.2021.01.054.

Kotwa JD, Jamal AJ, Mbareche H, Yip L, Aftanas P, Barati S, Bell NG, Bryce E, Coomes E, Crowl G, Duchaine C, Faheem A, Farooqi L, Hiebert R, Katz K, Khan S, Kozak R, Li AX, Mistry HP, Mozafarihashjin M, Nasir JA, Nirmalarajah K, Panousis EM, Paterson A, Plenderleith S, Powis J, Prost K, Schryer R, Taylor M, Veillette M, Wong T, Zhong XZ, McArthur AG, McGeer AJ, Mubareka S. Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada. medRxiv. Le 20 mai 2021. doi: 10.1101/2021.05.17.21257122.

Merckx J, Cooke S, Tal TE, Laxer RM, Bitnun A, Morris SK, Yeh EA, Yea C, Gill P, Papenburg J, Lefebvre M-A, Ulloa-Gutierrez R, Brenes-Chacon H, Yock-Corrales A, Ivankovich-Escoto G, Soriano-Fallas A, Hernandez-de Mezerville M, Dewan T, Restivo L, Nateghian A, Haghighi Aski B, Manafi A, Dwilow R, Bullard J, Lopez A, Sadarangani M, Roberts A, Barton M, Petel D, Le Saux N, Bowes J, Purewal R, Lautermilch J, Tehseen S, Bayliss A, Wong JK, Leifso K, Foo C, Robinson J. Multicenter cohort study of multisystem inflammatory syndrome in children (MIS-C). medRxiv. Le 19 mai 2021. doi: 10.1101/2021.05.14.21257058.

Tremblay K, Rousseau S, Zawati MH, Auld D, Chassé M, Coderre D, Falcone EL, Gauthier N, Grandvaux N, Gros-Louis F, Jabet C, Joly Y, Kaufmann DE, Laprise C, Larochelle C, Maltais F, Mes-Masson A-M, Montpetit A, Piché A, Richards JB, Tse SM, Turgeon AF, Turecki G, Vinh DC, Wang HT, Mooser V,on behalf of BQC19. The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLOS ONE. Le 19 mai 2021;16(5): e0245031. doi: 10.1371/journal.pone.0245031.

Lewin A, Therrien R, De Serres G, Grégoire Y, Perreault J, Drouin M, Fournier M-J, Tremblay T, Beaudoin J, Beaudoin-Bussières G, Prévost J, Gendron-Lepage G, Finzi A, Bernier F, Bazin R, Germain M, & Delage G. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study. Can J Public Health. Le 17 mai 2021. doi: 10.17269/s41997-021-00531-6.

Saeed S, Uzicanin S, Lewin A, Lieshout-Krikke R, Faddy H, Erikstrup C, Osiowy C, Seed C, Steele W, Davidson K, Custer B, O’Brien S. Current challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies among blood donors: A scoping review. medRxiv [Preprint]. Le 17 mai 2021. doi: 10.1101/2021.05.13.21257177.

Gobeil P, Pillet S, Séguin A, Boulay I, Mahmood A, Vinh DC, Charland N, Boutet P, Roman F, Most RVD, Ceregido Perez MDLA, Ward BJ, Landry N. Interim report of a phase 2 randomized trial of a plant-produced virus-like particle vaccine for Covid-19 in healthy adults aged 18-64 and older adults aged 65 and older. medRxiv [Preprint]. Le 14 mai 2021. doi: 10.1101/2021.05.14.21257248.

Campbell JR, Dion C, Uppal A, Yansouni CP, Menzies D. Systematic testing for SARS-CoV-2 infection among essential workers in Montréal, Canada: A prospective observational and cost assessment study. medRxiv [Preprint]. Le 14 mai 2021. doi: 10.1101/2021.05.12.21256956.

Saeed S, O’Brien SF, Abe K, Yi O, Rathod B, Wang J, Fazel-Zarandi M, Tuite A, Fisman D, Wood H, Colwill K, Gingras A-C, Drews S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. medRxiv [Preprint]. Le 12 mai 2021. doi: 10.1101/2021.05.11.21256992.

Liu J, Budylowski P, Samson R, Griffin BD, Babuadze G, Rathod B, Colwill K, Abioye JA, Schwartz JA, Law R, Yip L, Ahn SK, Chau S, Naghibosadat M, Arita Y, Hu Q, Yue FY, Banerjee A, Mossman K, Mubareka S, Kozak RA, Pollanen MS, Orozco NM, Gingras A-C, Marcusson EG, Ostrowski MA. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. bioRxiv [Preprint]. Le 12 mai 2021. doi: 10.1101/2021.05.11.443286.

Hossenbaccus L, Linton S, Ramchandani R, Gallant M, Ellis AK, Insights into allergic risk factors from birth cohort studies. Ann. Allergy Asthma Immunol. Le 7 mai 2021. doi: 10.1016/j.anai.2021.04.025.

GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs (Kaushic C). Priorities for COVID-19 research response and preparedness in low-resource settings. Lancet. Le 6 mai 2021;397(10288):1866-1868. doi: 10.1016/S0140-6736(21)00980-6.

Sjaarda CP, Guthrie JL, Mubareka S, Simpson JT, Hamelin B, Wong H, Mortimer L, Slinger R, McArthur AG, Desjardins M, McGeer A, Mazzulli T, Douchant K, Brabant-Kirwan D, Fattouh R, Campigotto A, Patel SN, Fittipaldi N, Colautti RI, Sheth PM for the Ontario’s COVID-19 Genomics Rapid Response Coalition. Temporal dynamics and evolution of SARS-CoV-2 demonstrate the necessity of ongoing viral genome sequencing in Ontario, Canada. mSphere. Le 5 mai 2021;6(3):e00011-21. doi: 10.1128/mSphere.00011-21.

Watt JA, Lane NE, Veroniki AA, Vyas MV, Williams C, Ramkissoon N, Thompson Y, Tricco AC, Straus SE, Goodarzi Z. Diagnostic accuracy of virtual cognitive assessment and testing: Systematic review and meta-analysis. J Am Geriatr Soc. Le 4 mai 2021. doi: 10.1111/jgs.17190.

Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, Fergusson DA, Cushing MM, Glesby MJ, Chassé M, Devine DV, Robitalle N, Bazin R, Shehata N, Finzi A, McGeer A, Scales DC, Schwartz L, Turgeon AF, Zarychanski R, Daneman N, Carl R, Amorim L, Gabe C, Ellis M, Sachais BS, Loftsgard KC, Jamula E, Carruthers J, Duncan J, Lucier K, Li N, Liu Y, Armali C, Kron A, Modi D, Auclair MC, Cerro S, Avram M, Arnold DM. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. Le 4 mai 2021;22(1):323. doi: 10.1186/s13063-021-05235-3.

Caulley L, Shaw J, Corsten M, Hua N, Angel JB, Poliquin G, Whelan J, Antonation K, Johnson-Obaseki S. Salivary testing of COVID-19: evaluation of serological testing following positive salivary results. BMC Infect Dis. Le 4 mai 2021;21(1):410. doi: 10.1186/s12879-021-06108-5.

Nieuwlaat R, Mbuagbaw L, Mertz D, Burrows LL, Bowdish DME, Moja L, Wright GD, Schünemann HJ. Coronavirus disease 2019 and antimicrobial resistance: parallel and interacting health emergencies. Clin Infect Dis. Le 4 mai 2021;72(9):1657-1659. doi: 10.1093/cid/ciaa773.

Stone M, Germanio CD, Wright DJ, Sulaeman H, Dave H, Fink RV, Notari EP, Green V, Strauss D, Kessler D, Destree M, Saa P, Williamson PC, Simmons G, Stramer SL, Opsomer J, Jones JM, Kleinman S, Busch MP, for the NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P). Use of U.S. blood donors for national serosurveillance of SARS-CoV-2 antibodies: Basis for an expanded national donor serosurveillance program. medRxiv [Preprint]. Le 3 mai 2021. doi: 10.1101/2021.05.01.21255576.

Norton A, Olliaro P, Sigfrid L, Carson G, Paparella G, Hastie C, Kaushic C, Boily-Larouche G, Suett JC, O’Hara M; ISARIC and GloPID-R Long COVID Forum Working Group. Long COVID: tackling a multifaceted condition requires a multidisciplinary approach. Lancet Infect Dis. Le mai 2021;21(5):601-602. doi: 10.1016/S1473-3099(21)00043-8.

Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Borzutzky A, Damsgaard CT, Dubnov-Raz G, Esposito S, Gilham C, Ginde AA, Golan-Tripto I, Goodall EC, Grant CC, Griffiths CJ, Hibbs AM, Janssens W, Khadilkar AV, Laaksi I, Lee MT, Loeb M, Maguire JL, Majak P, Mauger DT, Manaseki-Holland S, Murdoch DR, Nakashima A, Neale RE, Pham H, Rake C, Rees JR, Rosendahl J, Scragg R, Shah D, Shimizu Y, Simpson-Yap S, Kumar GT, Urashima M, Martineau AR. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. Le mai 2021;9(5):276 – 292. doi: 10.1016/S2213-8587(21)00051-6.

Vijh R, Ghafari C, Hayden A, Schwandt M, Sekirov I, Morshed M, Levett P, Krajden M, Boraston S, Daly P, Lysyshyn M, Harding J, McLennan M, Chahil N, Mak A, McKee G. Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia: Implications for outbreak management and infection control policies. Am J Infect Control. Le mai 2021;49(5):649-652. doi: 10.1016/j.ajic.2020.10.009.

Matic N, Lawson T, Ritchie G, Stefanovic A, Leung V, Champagne S, Romney MG, Lowe CF. Automated molecular testing of saliva for SARS-CoV-2 detection. Diagn Microbiol Infect Dis. Le mai 2021;100(1):115324. doi: 10.1016/j.diagmicrobio.2021.115324.

Alsharrah D, Alhaddad F, Alyaseen M, Aljamaan S, Almutairi N, Ayed M, Papenburg J, Alghounaim M. Clinical characteristics of pediatric SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) in Kuwait. J Med Virol. Le mai 2021;93(5):3246-3250. doi: 10.1002/jmv.26684.

Lewin A, Drews SJ, Lieshout‐Krikke R, Erikstrup C, Saeed S, Fady H, Uzicanin S, Custer B, O’Brien SF. An international comparison of anti‐SARS‐COV‐2 assays used for seroprevalence surveys from blood component providers. Vox Sang. Le 29 avril 2021. doi: 10.1111/vox.13100.

Sundaram ME, Calzavara A, Mishra S, Kustra R, Chan AK, Hamilton MA, Djebli M, Rosella LC, Watson T, Chen H, Chen B, Baral SD, Kwong JC. Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. CMAJ. Le 27 avril 2021. doi: 10.1503/cmaj.202608.

Curran J, Dol J, Boulos L, Somerville M, McCulloch H, MacDonald M, LeBlanc J, Barrett L, Hatchette T, Comeau J, Reynolds B, Shin D, Gallant A, Wong H, Crowther D, Yu Z. Transmission characteristics of SARS-CoV-2 variants of concern Rapid Scoping Review. medRxiv. Le 25 avril 2021. doi: 10.1101/2021.04.23.21255515.

Watkins-Martin K, Orri M, Pennestri M-H, Castellanos-Ryan N, Larose S, Gouin J-P, Ouellet-Morin I, Philippe F, Boivin M, Tremblay RE, Côté SM, Geoffroy M-C. Depression and anxiety symptoms in young adults before and during the Covid-19 pandemic: Evidence from a Canadian population-based cohort. medRxiv. Le 23 avril 2021. doi: 10.1101/2021.04.23.21255994.

Banerjee A, El-Sayes N, Budylowski P, Jacob RA, Richard D, Maan H, Aguiar JA, Demian WL, Baid K, D’Agostino MR, Ang JC, Murdza T, Tremblay B.J.-M, Afkhami S, Karimzadeh M, Irving AT, Yip L, Ostrowski M, Hirota JA, Kozak R, Capellini TD, Miller MS, Wang B, Mubareka S, McGeer AJ, McArthur AG, Doxey AC, Mossman K, Experimental and natural evidence of SARS-CoV-2 infection-induced activation of type I interferon responses. ISCIENCE. Le 23 avril 2021. doi: 10.1016/j.isci.2021.102477.

REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. Le 22 avril 2021;384(16):1491-1502. doi: 10.1056/NEJMoa2100433.

Lebrasseur A, Fortin-Bédard N, Lettre J, Raymond E, Bussières EL, Lapierre N, Faieta J, Vincent C, Duchesne L, Ouellet MC, Gagnon E, Tourigny A, Lamontagne MÈ, Routhier F. Impact of the COVID-19 pandemic on older adults: rapid review. JMIR Aging. Le 12 avril 2021;4(2):e26474. doi: 10.2196/26474.

Furman E, Cressman A, Shin S, Kuznetsov A, Razak F, Verma A, Diamant A. Prediction of personal protective equipment use in hospitals during COVID-19. Health Care Manag Sci. Le 12 avril 2021:1–15. doi: 10.1007/s10729-021-09561-5.

Bullard J, Funk D, Dust K, Garnett L, Tran K, Bello A, Strong JE, Lee SJ, Waruk J, Hedley A, Alexander D, Caeseele PV, Loeppky C, Poliquin G. Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults. CMAJ. Le 9 avril 2021;cmaj.210263. doi: 10.1503/cmaj.210263.

McAlister FA, Bushnik T, Leung AA, Saxinger L. Informing COVID-19 vaccination priorities based on the prevalence of risk factors among adults in Canada. CMAJ. Le 9 avril 2021;cmaj.210529. doi: 10.1503/cmaj.210529.

Verma AA, Razak F. Lessons for hospital care from the first wave of COVID-19 in Ontario, Canada. Hosp Pract. Le 9 avril 2021. doi: 10.1080/21548331.2021.1915657

Watson T, Kwong JC, Kornas K, Mishra S, Rosella LC. Neighbourhood characteristics associated with the geographic variation in laboratory confirmed COVID-19 in Ontario, Canada: a multilevel analysis. medRxiv. Le 9 avril 2021. doi: 10.1101/2021.04.06.21254988.

Sadarangani M, Abu Raya B, Conway JM, Iyaniwura SA, Falcao RC, Colijn C, Coombs D, Gantt S. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. Le 8 avril 2021;39(15):2020-2023. doi: 10.1016/j.vaccine.2021.03.020.

Goupil R, Benlarbi M, Beaubien-Souligny W, Nadeau-Fredette A-C, Chatterjee D, Goyette G, Lamarche C, Tom A, Finzi A, Suri RS. Short-term antibody response and tolerability after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study. medRxiv. Le 8 avril 2021. doi: 10.1101/2021.03.30.21254652.

Mishra S, Ma H, Moloney G, You KCY, Darvin D, Landsman D, Kwong JC, Calzavara A, Straus S, Chan AK, Gournis E, Rilkoff H, Xia Y, Katz A, Williamson T, Malikov K, Kustra R, Maheu-Giroux M, Sander B, Baral SD. Increasing concentration of COVID-19 by socioeconomic determinants and geography in Toronto, Canada: an observational study. medRxiv. Le 6 avril 2021. doi: 10.1101/2021.04.01.21254585.

Fell DB, Dimitris MC, Hutcheon JA, Ortiz JR, Platt RW, Regan AK, Savitz DA. Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy. Vaccine. Le 1 avril 2021;39(14):1882-1886. doi: 10.1016/j.vaccine.2021.02.070.

Nikiforuk AM, Kuchinski KS, Twa DDW, Lukac CD, Sbihi H, Basham CA, Steidl C, Prystajecky NA, Jassem AN, Krajden M, Patrick DM, Sekirov I. The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: A cross-sectional study of people tested for COVID-19 in British Columbia, Canada. EBioMedicine. Le 1 avril 2021;66:103316. doi: 10.1016/j.ebiom.2021.103316.

Cholette F, Mesa C, Harris A, Ellis H, Cachero K, Lacap P, Galipeau Y, Langlois M-A, Gingras A-C, Yansouni CP, Papenburg J, Cheng MP, Chakraborty P, Stein DR, Caeseele PV, Barlett S, Krajden M, Goldfarb D, McGeer A, Osiowy C, Hankins C, Mazer B, Drebot M, Kim J. Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. Research Square [Preprint]. Le 1 avril 2021. doi: 10.21203/rs.3.rs-366992/v1.

Valcourt EJ, Manguiat K, Robinson A, Chen JC, Dimitrova K, Philipson C, Lamoureux L, McLachlan E, Schiffman Z, Drebot MA, Wood H. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis. Le avril 2021;99(4):115294. doi: 10.1016/j.diagmicrobio.2020.115294.

Carson G, Sigfrid L, Olliaro P, Norton A, Paparella G, Matulevics R, Gillesen A, Horby P, Hastie C, O’Hara M, Suett J, Moore S, Vaux R, Habarugira JM, Boily-Larouche G, Clark E, Hart P, Golding J, Madelaine C, Mackenwells B, Ruze K, Jamieson N, Resende L, Depoortere E, Kinsey A, Munblit D, Hanna F, Diaz J, Wilder-Smith A, Wiysonge C, Kaushic C, Reyes LF, Bruzzone R, Yazdanpanah Y, Ghebreyesus TA, Blydenstein AV, Keita A, Siqueira A, Cheung A, Stavropoulou C, Simpson F, Scott J, Breen J, Fokam J, Baillie K, Netravathi M, Herridge M, Alwan N, Rupali P, Zarychanski R, Choi S-H, Mlaba L, Badio M, Mewar B, G Assaf, Brightling C, Altmann D, Bozza F, Hung I, Ohmagari N, Singh S, Morioka S, Hatcher S, Piva S. Research priorities for Long Covid: refined through an international multi-stakeholder forum. BMC Med. Le 31 mars 2021;19(84). doi: 10.1186/s12916-021-01947-0.

Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, Feng JL, Mize G, De Rosa SC, Finzi A, Lemos MP, Cohen KW, Moodie Z, McElrath J, McGuire AT. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. Le 25 mars 2021. doi: 10.1126/science.abg9175.

Cojocaru R, Yaseen I, Unrau PJ, Lowe CF, Ritchie G, Romney MG, Sin DD, Gill S, Slyadnev M. Microchip RT-PCR Detection of Nasopharyngeal SARS-CoV-2 Samples. J Mol Diagn. Le 8 mars 2021. doi: 10.1016/j.jmoldx.2021.02.009.

Morshed M, Sekirov I, McLennan M, Levett PN, Chahil N, Mak A, Carruthers E, Pidduck T, Kustra J, Laley J, Lee M-K, Chu K, Burgess F, Vijh R, Willis L, Wada R, Blancaflor R, Boraston S, Hayden A, Krajden M. Comparative analysis of capillary vs venous blood for serologic detection of SARS-CoV-2 antibodies by RPOC lateral flow tests. Open Forum Infect. Dis. Le 8 mars 2021;8(3). doi: 10.1093/ofid/ofab043.

Barton M, Papenburg J, Ulloa-Gutierrez R, Brenes-Chacon H, Yock-Corrales A, Ivankovich-Escoto G, Soriano-Fallas A, Mezerville MH, Bitnun A, Morris SK, El Tal T,  Yeh EA, Gill P, Laxer R, Nateghian A, Aski BH, Manafif A, Lefebvre M-A, Caya C, Cooke  S, Dewan T, Restivo L, Viel-Thériault I, Trajtman A, Dwilow R, Bullard J, Sadarangani M, Roberts A, Le Saux N, Bowes J, Wong JK, Purewal R, Lautermilch J, Leifso K, Foo C, Newhook LA, Bayliss A, Petel D, Robinson J on behalf of the Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC). Multicenter cohort study of children hospitalized with SARS-CoV-2 infection. MedRxiv. Le 23 février 2021. doi.org/10.1101/2021.02.19.21251340.

Therrien C, Serhir B, Bélanger-Collard M, Skrzypczak J, Shank DK, Renaud C, Girouard J, Loungnarath V, Carrier M, Brochu G, Tourangeau F, Gilfix B, Piche A, Bazin R, Guérin R, Lavoie M, Martel-Laferrière V, Fortin C, Benoit A, Marcoux D, Gauthier N, Laumaea AM, Gasser R, Finzi A, Roger M. Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories. J Clin Microbiol. Le 18 février 2021;59(3):e02511-20. doi: 10.1128/JCM.02511-20.

Ismail SJ, Zhao L, Tunis MC, Deeks SL, Quach C. Key populations for early COVID-19 immunization: preliminary guidance for policy. CMAJ. Le 30 novembre 2020;192(48):E1620-32. doi: 10.1503/cmaj.202353.

Perreault J, Tremblay T, Fournier MJ, Drouin M, Beaudoin-Bussières G, Prévost J, Lewin A, Bégin P, Finzi A, Bazin R. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood. Le 26 novembre 2020;136(22):2588-2591. doi: 10.1182/blood.2020008367.

Vijh R, Ghafari C, Hayden A, Schwandt M, Sekirov I, Morshed M, Levett P, Krajden M, Boraston S, Daly P, Lysyshyn M, Harding J, McLennan M, Chahil N, Mak A, McKee G. Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia: Implications for outbreak management and infection control policies. Am J Infect Control. Le 18 octobre 2020. doi: 10.1016/j.ajic.2020.10.009.

Kohler PP, Kahlert CR, Sumer J, Flury D, Güsewell S, Leal-Neto OB, Notter J, Albrich WC, Babouee Flury B, McGeer A, Kuster S, Risch L, Schlegel M, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. Infect Control Hosp Epidemiol. Le octobre 2020;8:1-5. doi: 10.1017/ice.2020.1244.

Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc F, Budylowski P, Li A, Paterson A, Yue FY, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M, Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras AC. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol. Le 8 octobre 2020;5(52):eabe5511. doi: 10.1126/sciimmunol.abe5511.

Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis AP 2nd, Girardin RC, Rathod B, Wang JH, Barrios-Rodiles M, Colwill K, McGeer AJ, Mubareka S, Gommerman JL, Durocher Y, Ostrowski M, McDonough KA, Drebot MA, Drews SJ, Rini JM, Gingras AC. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. Le 25 octobre 2020;5(19):e142362. doi: 10.1172/jci.insight.142362.

Van Caeseele P, Bailey D, Forgie SE, Dingle TC, Krajden M. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health. CMAJ. Le 24 aout 2020;192(34):E973-E979. doi: 10.1503/cmaj.201588.

Anderson G, Frank JW, Naylor CD, Wodchis W, Feng P. Using socioeconomics to counter health disparities arising from the covid-19 pandemic. BMJ. Le 8 juin 2020;369:m2149. doi: 10.1136/bmj.m2149.

Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, Caya C, Semret M, Quach C, Libman M, Mazzola L, Sacks JA, Dittrich S, Papenburg J. Serodiagnostics for severe acute respiratory syndrome–related coronavirus 2: a narrative review. Ann Intern Med. Le 4 juin2020;173(6):450-460. doi: 10.7326/M20-2854.

Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S, Yansouni CP. Diagnostic testing for severe acute respiratory syndrome–related coronavirus 2: a narrative review. Ann Intern Med. Le 2 juin 2020;172(11):726-734. doi: 10.7326/M20-1301.

Aller en haut de la page